



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Current trends in the treatment of HR+/HER2+ breast cancer

Citation for published version:

Kay, C, Martinez-Perez, C, Meehan, J, Gray, M, Webber, V, Dixon, JM & Turnbull, AK 2021, 'Current trends in the treatment of HR+/HER2+ breast cancer', *Future oncology*, vol. 17, no. 13, pp. 1665-1681.
<https://doi.org/10.2217/fon-2020-0504>

Digital Object Identifier (DOI):

[10.2217/fon-2020-0504](https://doi.org/10.2217/fon-2020-0504)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Future oncology

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Current trends in the treatment of hormone receptor positive/HER2-positive breast cancer

Journal:	<i>Future Oncology</i>
Manuscript ID	FON-2020-0504.R2
Manuscript Type:	Review
Keywords:	Breast Cancer, Hormone receptor, Endocrine therapy, Hormonal therapy, HER2-positive, Triple positive breast cancer, Clinical trials, Combination treatment, HR+/HER2+, Emerging therapeutics

SCHOLARONE™
Manuscripts

Abstract

Treatment for hormone receptor-positive/human epidermal growth factor receptor 2-positive (HR+/HER2+) patients has been debated, as some tumours within this luminal HER2+ subtype behave like luminal A cancers, while others like non-luminal HER2+ breast cancers. Recent research and clinical trials have revealed a combination of hormone and targeted anti-HER2 approaches without chemotherapy provides long-term disease control for at least some HR+/HER2+ patients. Novel anti-HER2 therapies, including neratinib and ado-trastuzumab emtansine, and new agents that are effective in HR+ cancers, including the next generation of oral selective oestrogen receptor downregulators/degraders (SERDS) and CDK4/6 inhibitors such as palbociclib, are now being evaluated in combination. This review discusses current trials and results from previous studies that will provide the basis for current recommendations on how to treat newly diagnosed patients with HR+/HER2+ disease.

Lay abstract

About 10% of all breast cancer tumours are both hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) positive. It is clear that some patients with this type of breast cancer will require only hormone therapy (HT) aimed at HRs and others will require a combination of HT and drugs targeted at HER2. This review discusses current clinical trials and results from previous studies of patients with HR+/HER2+ disease.

Keywords

Breast Cancer, Hormone receptor, HER2-positive, HR+/HER2+, Triple positive breast cancer, luminal HER2, Clinical trials, Combination treatment, Emerging therapeutics

1. Introduction

Breast cancer is the most common cancer in women worldwide, with over 2 million new diagnoses in 2018 alone [1]. Patients with breast cancer are stratified and treated based on the expression status of certain receptors in their tumour. Identification of the oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) enabled the first stratification according to tumour biology. These receptors have proved to be important prognostic and predictive biomarkers in women with breast cancer. To determine the presence and amount of ER, PR and HER2 protein expressed, immunohistochemistry (IHC) is used and a pathologist assigns a score for each. For ER and PR, the percentage and intensity of staining is measured. These can be combined to create what is known as a histoscore or an Allred score; the latter score is 0 when negative and between 2 and 8 if positive [2]. These receptors are often classified as overall positive (+) or negative (-) despite there being wide variations in the level of positivity in both ER and PR. HER2 status is assessed according to the intensity of staining as 0, 1+, 2+ or 3+. HER2 tumours with scores of 0 and 1+ are considered HER2-negative, 2+ tumours are deemed equivocal and require further testing to determine positive/negative status, while 3+ is considered HER2-positive. A variety of in situ hybridisation tests, including fluorescence in-situ hybridisation (FISH), are used in 2+ HER2 cancers to assess whether there is amplification of the *HER2* gene and if so, these cancers are also classified as HER2-positive.

1
2
3 42 Hormone receptor-positive (HR+) breast cancers are those that express ER, PR or
4 43 both. These tumours account for 70-80% of all breast cancers [3]. These hormone-
5 44 dependent cancers can often be treated successfully with a variety of drugs that modulate
6 45 the oestrogen receptor or reduce oestrogen. HER2+ breast cancers tend to be associated
7 46 with a worse prognosis than HER2- breast cancers [4], although the emergence of targeted
8 47 HER2 therapies such as trastuzumab and pertuzumab has improved outcomes for HER2+
9 48 disease [5,6]. There remains a group of women who recur despite these anti-HER2 therapies
10 49 and whose outlook remains poor.

11
12
13
14 50 Among the most significant discoveries in breast cancer has been the identification
15 51 of breast cancer subtypes with distinct biological characteristics that translate into
16 52 differences in prognosis and response to treatments [7]. The subtypes are Luminal A,
17 53 Luminal B, HER2-enriched, Basal-like and Normal-like. The presence or absence of ER, PR
18 54 and HER2 largely align with these five molecular subtypes as shown in Figure 1. Stratification
19 55 of breast cancers into these subgroups has been the focus of much research in recent years
20 56 in the hopes of allowing each patient to be treated with therapy optimal to their specific
21 57 cancer subtype. Several multigene predictive and prognostic signatures are now available
22 58 commercially to aid treatment decisions, with Prosigna's Breast Cancer Prognostic Gene
23 59 Signature Assay (previously known as the PAM50 test) designed specifically based on the
24 60 intrinsic subtypes [8]. Studies evaluating this are underway.

25
26
27
28 61 The aim of this review is to explore the subgroup of patients that have cancers that
29 62 are both HR and HER2 positive. Known as the luminal HER2 subgroup, cancers that are both
30 63 HR+ and HER2+ have a complex interaction between the endocrine and HER2 pathways
31 64 linked to these receptors. Traditionally, there are three main treatment options for this
32 65 subgroup of breast tumours: (i) hormone therapy alone, (ii) targeted anti-HER2 therapy and
33 66 chemotherapy combined with later hormone therapy, or (iii) primary hormone therapy
34 67 followed later by targeted anti-HER2 therapy and chemotherapy. This review will focus on
35 68 tumour biology and hormone, anti-HER2 and combination therapies currently available for
36 69 the luminal HER2 subgroup. Recently completed clinical trials and those currently underway
37 70 will be summarised.

71 **2. Hormone and targeted therapies for invasive breast cancer**

72 **2.1. Hormone therapy**

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

HR+ breast cancer is treated with hormone therapy, also known as endocrine therapy or anti-oestrogen therapy. The view of HR+ cancers is that they are dependent on oestrogen for their growth and survival, so targeting this hormone, its signalling and its downstream effects is an important therapeutic strategy. In premenopausal women, the main source of oestrogen is the ovaries. Therapeutic strategies include (i) stopping oestrogen production by ovarian ablation (surgically removing them via oophorectomy) or temporarily suppressing ovarian function with gonadotropin releasing hormone (GnRH) agonists (which will initiate menopause), or (ii) blocking the effect of oestrogen on the cancer with drugs that target the oestrogen receptor. Studies have shown that between 5 and 10 years of hormone therapy in HR+ breast cancers significantly improves survival. In premenopausal women, hormone therapy options are tamoxifen alone or an LHRH analogue combined with tamoxifen or an aromatase inhibitor. Tamoxifen is a selective oestrogen receptor modulator (SERM) that is a partial ER agonist, blocking the activation of oestrogen receptor by oestrogen in the breast but acting as an agonist on the ER of the

1
2
3 87 endometrium and the skeleton. Tamoxifen was first given to women with breast cancer in
4 88 the early 1970s [9] and it has saved countless lives. Recent studies in premenopausal
5 89 women show that compared with tamoxifen alone, a combination of LHRH or
6 90 oophorectomy and tamoxifen or aromatase inhibitors produces an even greater
7 91 improvement in survival, although this comes with a greater incidence of adverse events.

10 92 In postmenopausal women, most of the body's oestrogen is synthesised peripherally
11 93 in the liver, fat and locally in the breast from androgen precursors released from the adrenal
12 94 gland through a reaction catalysed by the enzyme aromatase. An aromatase inhibitor (AI)
13 95 given to postmenopausal women thus stops the production of oestrogen. AIs currently
14 96 available include the non-steroidal letrozole and anastrozole and the steroidal exemestane.
15 97 Tamoxifen together with selective oestrogen receptor downregulators or degraders
16 98 (SERDs), such as the ER antagonist fulvestrant are other alternative therapies in ER+ breast
17 99 cancers. SERDS induce a conformational change in ER that prevents the binding of
18 100 oestrogen and leads to degradation of the receptor. Fulvestrant, an injectable SERD, is
19 101 currently the only SERD available and is most often used to treat recurrent or metastatic
20 102 ER+/HER2- breast cancer in postmenopausal women who have recurred on prior endocrine
21 103 therapy. New oral SERDS are currently being developed and tested [10–12].

104 2.2. HER2-targeted therapy

105 The emergence of anti-HER2 therapies has led to significant improvements in the
106 prognosis and outcome for patients with HER2+ breast cancers. Trastuzumab, a
107 recombinant humanised monoclonal antibody, targets an extracellular domain of HER2,
108 preventing its dimerisation with other HER receptors to halt cancer growth [13,14].
109 Pertuzumab, another monoclonal antibody, acts on a different extracellular domain of HER2
110 and halts dimerisation particularly of HER2 with HER3, the most growth-promoting
111 dimerisation of the HER family of receptors [15]. Combinations of trastuzumab and
112 pertuzumab with chemotherapy are more effective than either drug alone with
113 chemotherapy. Lapatinib is a dual tyrosine kinase inhibitor of both HER2 and HER1 (EGFR)
114 that was approved by the United States Food and Drug Administration (FDA) for use in
115 combination with the chemotherapy drug capecitabine in 2007 [16]. Lapatinib can also be
116 given together with trastuzumab [17] and this combination provides a more complete
117 blockade of HER signalling than either alone [18]. Neratinib, a tyrosine kinase inhibitor, is a
118 pan-HER inhibitor, licensed and currently recommended by the UK's National Institute for
119 Health and Care Excellence (NICE) in the technology appraisal guidance TA612 for use as
120 extended adjuvant treatment following trastuzumab in patients with ER+/HER2+ breast
121 cancer [19]. Trastuzumab emtansine (T-DM1), also known as ado-trastuzumab emtansine, is
122 an antibody-drug conjugate in which trastuzumab is linked to the cytotoxic agent DM1 [20].
123 This was approved by the U.S. FDA in 2013 for the treatment of HER2+ metastatic breast
124 cancer and in 2019 for patients with HER2+ early breast cancer who have residual disease
125 following neoadjuvant trastuzumab and a taxane. In the UK, T-DM1 is recommended for the
126 treatment of HER2+ advanced breast cancer following treatment with trastuzumab and a
127 taxane [21]. Trastuzumab deruxtecan is an antibody drug combination comprising
128 trastuzumab and a cytotoxic topoisomerase I inhibitor and has broader anti-tumour activity
129 than T-DM1, including efficacy against low HER2-expressing tumours [22]. There is a series
130 of other anti-HER2 drugs in development and in early clinical trials.

131 2.3. Other targeted therapies for invasive breast cancer

1
2
3 132 The emergence of CDK4/6 inhibitors in recent years has provided another treatment
4 133 option [23]. These inhibitors induce cell cycle arrest, thereby stopping proliferation [24] and
5 134 all three drugs currently available (palbociclib, ribociclib and abemaciclib) have been
6 135 combined with endocrine therapy to treat HR+/HER2- advanced breast cancer [25]. Not as
7 136 much is known about the utility of CDK inhibitors in HR+/HER2+ disease, although trials of
8 137 CDK inhibitors in combination with endocrine therapies and anti-HER2 therapies are
9 138 currently underway (Table 1). Targeted therapies currently available for the treatment of
10 139 HR+ and/or HER2+ breast cancer, as single agents or in combination, are listed in Table 2.

14 140 **3. Complications treating HR+/HER2+ breast cancer**

15 141 **3.1. Worse prognosis for HR+/HER2+ subgroup**

16 142 The subgroup of HR+ breast cancers that also express HER2 has been shown to have
17 143 a significantly worse prognosis compared to other HR+ breast tumours [26]. These
18 144 HR+/HER2+ tumours account for about 10% of all breast cancers, or about half of all HER2+
19 145 tumours [27,28]. HR status in HER2+ tumours aligns with differences in response to
20 146 neoadjuvant treatment, location, type of metastases and survival [29,30].

21 147 Since the approval of trastuzumab (Herceptin), patients with HER2+ breast cancer
22 148 (including those that overexpress both ER (and/or PR) and HER2) have been treated with
23 149 chemotherapy and anti-HER2 therapy [5]; however, recent data has suggested there may be
24 150 other options. Combining hormone therapy with an anti-HER2 agent has proven beneficial
25 151 to some specific patients [31,32], particularly those presenting with tumours that are HER2+
26 152 and have high ER expression. These patients have a reduced response to trastuzumab plus
27 153 chemotherapy [33] but many are endocrine-sensitive, so combining trastuzumab and
28 154 endocrine therapy produces a high response rate and is an attractive option. However, not
29 155 all HR+/HER2+ tumours respond in the same manner. Identification of which patients
30 156 require single, sequential or combination treatments is an urgent need.

31 157 **3.2. Treatment resistance, tumour biology and HR/HER2 crosstalk**

32 158 Treating luminal HER2 breast cancer is complex; there is not one treatment or
33 159 combination of treatments that is suited to all patients with this subtype. Identifying what is
34 160 biologically driving the cancer can help (i.e. oestrogen or HER signalling and their
35 161 downstream effects), although pathway interaction and crosstalk can cause the cancer to
36 162 change course throughout treatment (Figure 2). HR+/HER2+ tumours often respond initially
37 163 to hormone therapy and/or HER2-targeted therapy but develop resistance over time [34].
38 164 One reason may be the known crosstalk between the ER and HER2 signalling pathways and
39 165 the involvement of other downstream pathways, such as PI3K and MAPK [35–39]. A study of
40 166 HER2+ cell lines showed an increase in ER or its downstream signalling targets following
41 167 treatment with lapatinib and trastuzumab, indicating ER signalling as a survival mechanism
42 168 for HER2+ cells [18]. Upregulation of ER signalling is also evident in HER2+ tumours treated
43 169 with trastuzumab, pertuzumab and lapatinib. In one study, 18% of HER2+ tumours that
44 170 were originally ER- were converted to ER+ following two weeks of neoadjuvant lapatinib,
45 171 providing further evidence of the interconnectedness of the ER and HER pathways [40].
46 172 Another study revealed primary resistance to T-DM1 in metastatic HER2+ breast cancer was
47 173 linked to there being negative *HER2* gene amplification in circulating tumour DNA and ER-
48 174 positivity and/or PR-positivity by IHC [41]. Investigations into ER and HER pathway
49 175 interactions are ongoing and include a study of Positron Emission Tomography with ¹⁸F-

1
2
3 176 fluoroestradiol (FES-PET) imaging as a tool to detect possible reversion of ER status in
4 177 patients with metastatic ER-/HER2+ breast cancer treated with trastuzumab, pertuzumab
5 178 and a taxane (Clinical Trial NCT03619044).

7 179 The mechanisms by which ER+/HER2+ tumours become resistant to their original
8 180 therapy remains unclear. The development of acquired resistance is complex and likely due
9 181 to multiple factors rather than just one. In addition to ER and HER2 pathway crosstalk,
10 182 resistance could also be caused by a loss or gain of ER overexpression resulting in reduced
11 183 efficacy of hormone therapy, existing or acquired mutations in the ER gene *ESR1* [42],
12 184 reactivation of HER2 [43] or acquired *HER2* mutations [44,45]. ER epigenetic changes have
13 185 also been described [46]. We are now advancing to the point where the tumour's endocrine
14 186 resistance profile should be assessed. For instance the timing (and measurement) of
15 187 acquired *ESR1* mutations in resistant cancers may be critical to dictate future endocrine
16 188 therapy [47,48]. Allouchery *et al* identified *ESR1* mutations at first relapse and at
17 189 progression on metastatic treatment, but these mutations were not present early during
18 190 adjuvant therapy [49]. It is also clear that a primary tumour and its recurrence(s) can differ
19 191 in hormone receptor positivity and temporal heterogeneity likely plays a role in treatment
20 192 resistance [45]. Assessment of ER, PR and HER2 in every breast cancer metastasis will help
21 193 improve selection of the most appropriate treatment.

22 194 Other potential targets that are involved in ER/HER crosstalk have also been
23 195 implicated recently. The enzyme fatty acid synthase (FASN) is known to be involved in
24 196 ER/HER2 crosstalk by way of the PI3K/AKT pathway. It was successfully inhibited by the
25 197 mTOR inhibitor rapamycin in ER+/HER2+ breast cancer cells and a combination of rapamycin
26 198 with the FASN inhibitor cerulenin induced apoptosis and inhibited cell migration and
27 199 tumorigenesis in ER+/HER2+ cells, suggesting FASN as a potentially new therapeutic target
28 200 [50]. The tyrosine kinase receptor IGF1R is also involved in ER/HER2 pathway crosstalk and
29 201 may also be a useful biomarker in ER+/HER2+ cancers. High expression of IGF1R is
30 202 associated with shorter disease-free survival in patients in this subgroup and inhibition of
31 203 both IGF1R and ER in breast cancer cell lines causes growth inhibition [51]. The addition of
32 204 trastuzumab inhibited growth further, suggesting this combined targeting of pathways could
33 205 be a successful approach for ER+/HER2+/IGF1R+ cancers. Other novel ideas to eliminate
34 206 ER/HER pathway crosstalk and successfully block multiple pathways include the use of
35 207 proteasome inhibitors [52] that have been successful in treating other types of cancer
36 208 including multiple myeloma, together with standard endocrine treatments. Targeting the
37 209 PI3 kinase pathways using PI3K inhibitors [53] such as alpelisib, approved by the U.S. FDA in
38 210 2019, combined with fulvestrant is one alternative. Finally, there are new anti-HER2
39 211 dendritic cell vaccines on the horizon [54].

40 212 As more research emerges regarding signalling pathway crosstalk [55] in triple
41 213 positive breast cancer and how this is related to resistance to therapies [56], it is clear that
42 214 for some women both ER and HER2 need to be targeted. This can be sequentially or with
43 215 combined therapy, but for some a single treatment may suffice. It is critical that we are able
44 216 to predict which patients require which treatment as more targeted endocrine and HER2
45 217 therapies are being developed and being trialled in combination studies.

4. Treating HR+/HER2+ breast cancer: What we've learned so far

4.1. Standard-of-care for HR+/HER2+ tumours

1
2
3 220 Historically, ER+/HER2+ breast cancer was treated with endocrine therapy combined
4 221 in some patients with chemotherapy. Following the development of trastuzumab
5 222 (Herceptin) in the 1990s [57], this group is now typically given chemotherapy and
6 223 trastuzumab followed by endocrine therapy to reduce the risk of recurrence. Some patients
7 224 with low risk HR+/HER2+ breast cancers are treated with adjuvant hormone therapy alone.
8 225 However, in most cases adjuvant chemotherapy is given in combination with trastuzumab
9 226 followed by endocrine therapy [58]. Clinicians take into account all factors including tumour
10 227 size and node status to avoid overtreatment, as some small node-negative tumours do well
11 228 with adjuvant endocrine therapy followed by trastuzumab and chemotherapy if they recur
12 229 [59]. Remarkably, a recent study investigating the treatment of HR+/HER2+ metastatic
13 230 breast cancer revealed that only 42% of the 6,234 patients ever received anti-HER2 therapy,
14 231 despite previous studies showing survival benefits for patients treated with both hormone
15 232 and anti-HER2 therapies [60]. Emerging novel drugs and combinations are being
16 233 investigated in clinical trials so eventually clear treatment strategies for patients with
17 234 HR+/HER2+ breast cancers should become available.

18 235 It has been suggested that HR+/HER2+ tumours should be treated as a distinct
19 236 molecular subtype of breast cancer. It should also be defined further based on other
20 237 characteristics to ensure that patients with these cancers receive appropriate treatment
21 238 whilst also avoiding overtreatment. Some tumours, particularly early-stage or smaller ones,
22 239 may be driven primarily by hormone receptor(s) and thus may not need HER2-targeted
23 240 treatment [61]. A recent study of patients with triple-positive breast cancer in Korea
24 241 showed that treatment with trastuzumab did not improve overall survival and that many of
25 242 these tumours behave clinically more like luminal A than HER2-enriched cancers [62].

26 243 **4.2. HR+/HER2+ metastatic breast cancer**

27 244 A number of previous clinical trials, summarised in Table 3, have been instrumental
28 245 in identifying new combination treatments for patients with HR+/HER2+ tumours. The
29 246 TAnDEM, EGF30008 and eLEcTRA phase III trials, all treating postmenopausal patients with
30 247 metastatic breast cancer, showed positive outcomes for the combination of an aromatase
31 248 inhibitor and trastuzumab or lapatinib. This included a progression-free survival (PFS)
32 249 benefit and, in 15% of TAnDEM patients, no disease progression for two years. However,
33 250 there was no overall survival (OS) benefit from the combined treatment [63–65].

34 251 One of the problems with studying HER2+ breast cancer is the variation in scoring
35 252 across centres. Discrepancies in testing methods and reproducibility of results have been
36 253 and remain a challenge [66,67]. Identifying which tumours are truly *HER2* amplified, with
37 254 *HER2* overexpressed, is critical to both retrospective survival studies and to the current
38 255 treatment issues for this subgroup of breast cancer. A retrospective analysis of metastatic
39 256 breast cancers showed some tumours that were deemed HER2-negative but were enriched
40 257 for HER2 could benefit from combined lapatinib and letrozole treatment [68]. Additionally,
41 258 changes to the American Society of Clinical Oncology (ASCO) treatment guidelines in 2018
42 259 reclassified some HER2+ tumours. Patients with cancers that were deemed equivocal in
43 260 assessment by IHC and FISH were reclassified as HER2-negative as there has not been any
44 261 proven benefit from HER2-targeted therapy in these individuals [69].

45 262 A combined hormone and anti-HER2 therapy approach clearly benefits some
46 263 patients, but the challenge lies in accurately identifying the subpopulation of patients likely

to gain additional benefit from a combined treatment strategy. The addition of pertuzumab improved overall survival in HER2+ patients in the CLEOPATRA study. The combination of trastuzumab, pertuzumab and docetaxel compared to just trastuzumab and docetaxel increased both PFS and OS in patients with HER2+ metastatic breast cancer. However, no significant difference in response was related to hormone receptor status [70]. NICE now recommends the combination of trastuzumab, pertuzumab and chemotherapy for treatment of metastatic HER2+ breast cancer [71] and also suggests the same strategy as an option in the neoadjuvant setting [72].

4.3. Neoadjuvant management of HR+/HER2+ breast cancer

The best approach to managing HR+/HER2+ breast cancer in the neoadjuvant setting has been the subject of debate. Chemotherapy has been shown to be much more beneficial in ER- disease; however, some women, particularly those of advanced age, struggle with toxic side effects [73,74]. The timing of chemotherapeutic or targeted, sequential or combined treatments is also being questioned for this group, with new evidence suggesting reducing or postponing the use of chemotherapy in favour of using targeted therapies, such as letrozole or trastuzumab [75]. Targeted treatment of breast cancer in the neoadjuvant setting has been useful, particularly for women with advanced age who may not tolerate chemotherapy well. Studies have shown neoadjuvant letrozole can shrink tumour size and induce gene expression changes in HR+ breast cancers [76,77] and that the addition of trastuzumab to neoadjuvant chemotherapy can increase the pathologic complete response (pCR) in HER2+ tumours [78].

Changes in current recommendations for chemotherapy in the neoadjuvant setting could be near, as new combination regimens have shown promising results. In the neoadjuvant phase II trial NA-PHER2 that combined palbociclib, fulvestrant and two anti-HER2 drugs (trastuzumab and pertuzumab), an objective clinical response was seen in 29/30 patients, as well as a decrease in proliferation (assessed by Ki67 expression) following two weeks of treatment prior to surgery [79]. Neoadjuvant palbociclib and letrozole produces effective clinical responses and decreases expression of the genes *IL6ST* and *RBBP8*, which have been associated with proliferation, in postmenopausal ER+/HER2- patients [80]. Biomarkers of response to neoadjuvant treatment are also emerging for ER+/HER2+ tumours, including a gene expression signature of retinoblastoma loss-of-function that has the potential to identify patients who would benefit from neoadjuvant chemotherapy [81]. Other predictive markers of poor response to neoadjuvant chemotherapy and HER2-targeted therapy in ER+/HER2+ patients are increased expression of stromal colXα1 and low levels of tumour-infiltrating lymphocytes [82]. Further research is still needed to identify which tumours within the complex HR+/HER2+ subgroup of breast cancers might benefit from specific single-agent and combined treatments in the neoadjuvant settings.

5. Where we are now: current trials and emerging therapeutic strategies

5.1. Metastatic and locally advanced HR+/HER2+ breast cancer

It is clear now that HR+/HER2- and HR+/HER2+ breast cancers have different biological characteristics, mechanisms of growth and response to treatment. Even within these groups of breast cancer there are inherent differences, with some HR+/HER2+ tumours behaving more like the luminal A subtype (i.e., ER-driven cancer) and others requiring a multipronged targeted blockade of the ER, PR and HER pathways. An improved

1
2
3 308 outcome from combination treatment with anti-HER2 therapy (trastuzumab or lapatinib)
4 309 and an AI is evident for some, but not all, HR+/HER2+ patients (TAnDEM, EGF3008, eLEcTRA
5 310 trials). Drugs like pertuzumab have improved response for some in this subgroup but its
6 311 addition is costly and may cause more adverse events (PERTAIN trial of metastatic or locally
7 312 advanced HR+/HER2+ breast cancer) [83].

8
9
10 313 Fulvestrant has also proven useful in the treatment of ER+/HER2+ patients with
11 314 multiple metastases who have received prior anti-HER2 therapy in combination with
12 315 chemotherapy or an AI [84]. A clinical trial (NCT03289039) is currently investigating the
13 316 combination treatment of neratinib and fulvestrant in ER+/HER2+ metastatic or locally
14 317 advanced breast cancer [85] (Table 1). So far, 46 patients with HR+/HER2-mutant metastatic
15 318 breast cancer have been treated with neratinib and fulvestrant. This combination shows
16 319 positive results in patients who have been treated previously with various agents; in
17 320 particular, patients who had previously received fulvestrant or CDK4/6 inhibitors responded
18 321 well to the combined regimen. The rate of diarrhoea was similar to that of single-agent
19 322 neratinib and was not dose-limiting and no patients discontinued treatment because of it
20 323 [86].

21
22
23
24 324 Fulvestrant and palbociclib also show great promise when combined and both are
25 325 now being tested in combination with anti-HER2 therapies in the metastatic setting (Table
26 326 1). Palbociclib has previously been tested in patients with ER+/HER2- advanced breast
27 327 cancer who progressed on endocrine therapy and, together with fulvestrant, has been
28 328 shown to increase PFS compared to fulvestrant alone (PALOMA3 trial) [87]. Further analysis
29 329 of circulating tumour DNA from PALOMA3 trial participants revealed acquired mutations in
30 330 *RB1*, *ESR1* and *PI3KCA* associated with resistance following treatment with fulvestrant [88].
31 331 Combining palbociclib with endocrine therapies other than fulvestrant may avoid these
32 332 acquired mutations. A trial designed to determine the recommended dose of palbociclib in
33 333 combination with letrozole and T-DM1 in patients with ER+/HER2+ metastatic breast cancer
34 334 is currently recruiting patients (Clinical Trial NCT03709082) [89].

35
36
37
38 335 Additional CDK4/6 inhibitors including ribociclib and abemaciclib are also being
39 336 tested in current clinical trials of HR+/HER2+ patients (Table 1). Particularly noteworthy is
40 337 the treatment of advanced HR+/HER2+ breast cancer with abemaciclib, fulvestrant and
41 338 trastuzumab in the monarchHER phase 2 trial. This combination treatment not only proved
42 339 tolerable and safe but also improved PFS compared to standard-of-care trastuzumab plus
43 340 chemotherapy [90]. Another recent study evaluating a triplet combination is the
44 341 ALTERNATIVE phase 3 trial. This study too showed a PFS benefit from treating with a dual
45 342 HER2 blockade of lapatinib and trastuzumab plus an aromatase inhibitor in the treatment of
46 343 postmenopausal women with HR+/HER2+ metastatic breast cancer [91]. These triplet
47 344 combinations of therapies could truly change the way HR+/HER2+ breast cancer is treated
48 345 as they eliminate the need for chemotherapy and its often toxic side effects.

52 346 **5.2. Neoadjuvant management of HR+/HER2+ breast cancer**

53
54 347 In the neoadjuvant setting, it is unclear whether a combined anti-oestrogen and anti-
55 348 HER2 approach offers any significant improvement to current practice. While some patients
56 349 do have a positive clinical response to neoadjuvant treatment with letrozole and lapatinib
57 350 (Neo-ALL-IN), a decrease in the ER Allred score after neoadjuvant treatment was linked to
58 351 poor outcome [92]. In addition, depriving oestrogen with a LHRH agonist or with an AI

1
2
3 352 combined with neoadjuvant docetaxel, carboplatin, trastuzumab and pertuzumab did not
4 353 statistically improve response (B-52 trial) [93] (Table 3).

6 354 **5.3. Adjuvant management of HR+/HER2+ breast cancer**

8 355 One of the most promising drugs for the treatment of HR+/HER2+ breast cancers is
9 356 the pan-HER tyrosine kinase inhibitor neratinib. Results from the ExteNET trial showed one
10 357 year of extended adjuvant neratinib following neoadjuvant and adjuvant chemotherapy and
11 358 trastuzumab significantly reduced the risk of relapse in early-stage HER2+ breast cancer.
12 359 Interestingly, a greater benefit from neratinib was seen in HR+/HER2+ patients compared to
13 360 HR- patients [94]. Many of the HR+ patients were also receiving endocrine therapy,
14 361 suggesting that suppressing both pathways was required to improve invasive disease-free
15 362 survival. The U.S. FDA approved neratinib (Nerlynx) for extended adjuvant treatment of
16 363 early-stage, HER2+ breast cancer in 2017 and in the UK NICE now recommends neratinib for
17 364 extended adjuvant treatment of HR+/HER2+ early stage breast cancer after adjuvant
18 365 trastuzumab [19]. In a xenograft study, extended adjuvant therapy with neratinib plus
19 366 fulvestrant maintained a prolonged complete response and blocked ER/HER2 crosstalk
20 367 [95,96].

25 368 **6. The need for a better understanding of the diverse biology of HR+/HER2+ and** 26 369 **associated biomarkers**

28 370 As shown by the evidence and studies summarised here, selection of the most
29 371 appropriate treatment strategy for the management of a patient that has a breast tumour
30 372 that is both HR+ and HER2+ poses a conundrum. The crux lies in the difficulty of determining
31 373 which receptors and their associated pathways are driving the tumour cells and what is the
32 374 interaction and crosstalk between them. A better understanding of the molecular diversity
33 375 within the subgroup of HR+/HER2+ breast cancer is essential before we can improve its
34 376 management.

37 377 There is now a need for biomarkers to predict response and recurrence. In the Neo-
38 378 ALL-IN trial of patients with ER+/HER2+ breast cancer, a number of predictors were
39 379 identified. These included a decrease in the ER Allred score after neoadjuvant treatment, an
40 380 SUVmax (a measure of activity in PET imaging linked to cell viability and proliferation) lower
41 381 than 5.5 on the baseline FES PET-CT and high baseline tumour-infiltrating lymphocytes of
42 382 over 20% [92]. These may be useful as biomarkers of response for future patients. Trefoil
43 383 factor 3 (TFF3) is another potential biomarker for resistance to trastuzumab, as its
44 384 expression is upregulated in trastuzumab-resistant ER+/HER2+ breast cancer cells and it has
45 385 been shown to activate HER family receptors [97].

49 386 IL6ST, a surrogate for endocrine therapy response [56], may also be a useful
50 387 biomarker for ER+/HER2+ breast cancer. In a study presented at the 2019 San Antonio
51 388 Breast Cancer Symposium, higher levels of IL6ST were associated with active ER signalling
52 389 and predicted clinical response to neoadjuvant letrozole in ER+/HER2+ tumours [98].
53 390 Importantly, lower levels of IL6ST were associated with a lack of response to endocrine
54 391 therapy and more active HER2 signalling. This supports the notion of a diverse underlying
55 392 biology within the ER+/HER2+ population, with two subgroups with distinct gene expression
56 393 profiles. These subgroups may be linked to differences in endocrine therapy responsiveness
57 394 and, importantly, might be easily stratified. IL6ST could potentially select ER+/HER2+

395 patients who need both endocrine and HER2-targeted therapy and others who should
396 receive endocrine therapy alone. Further work is needed both in the laboratory and within
397 clinical trials to better characterise those potential predictive signatures within the
398 ER+/HER2+ subgroup. ER+/HER2+ patient-derived xenografts (PDXs) have recently been
399 characterised and could provide a useful preclinical testing ground for new drugs and
400 combinations. Interestingly, the take rate in culture was higher for ER+/HER2+ tumours
401 compared to ER+/HER2- PDXs, possibly indicating a greater drive for survival [99].

402 7. Conclusion

403 In summary, the HR+/HER2+ breast cancer subtype consists of a range of cancers
404 with varying interaction between ER and HER2 receptors and pathways. Some HR+/HER2+
405 tumours behave more like the luminal A subtype and others are more like non-luminal
406 HER2+ disease. The latter will likely require more intensive treatment and appears to
407 respond better to combinations of endocrine and anti-HER2 targeted therapies. [The time of
408 giving the same treatments for all ER+/HER2+ cancers is over.](#)

409 More research into the use of drugs including neratinib, T-DM1, fulvestrant, novel
410 oral SERDS, and CDK4/6 inhibitors alone or in combination with each other or with more
411 traditional therapies is required. Such research will hopefully provide information on the
412 best treatment approaches for individual patients and their cancers, [as it is clear not all
413 HR+/HER2+ cancers behave the same.](#) Results from these studies must be combined with
414 research to characterise the complex underlying biology of HR+/HER2+ disease, [in particular
415 the intricate interactions of the ER and HER2 pathways.](#) It is imperative that biomarkers of
416 response, disease progression and resistance are identified [in order to fully understand how
417 the disease progresses and be able to stratify patients for first, second and third-line
418 treatment if necessary.](#) Additional markers linked to molecular diversity will also be required
419 to help determine how best to treat individual patients with this breast cancer subtype. To
420 provide a truly individualised medicine there needs to be better characterisation of each
421 individual cancer both at diagnosis and recurrence. Markers including IL6ST will provide the
422 advances needed to achieve this goal.

423 424 Future perspective

425 As HR+/HER2+ breast cancer continues to be characterised as its own subgroup of
426 breast cancer of which there are at least two divisions (those which more closely resemble
427 luminal A cancers and others more similar to non-luminal HER2+ tumours), we are hopeful
428 that treatment for this subtype will become more personalised over the next 5-10 years
429 based on the outcome of recent and currently-ongoing trials. Some patients will require
430 combined treatment targeting both ER and HER2 signalling and others will need only
431 endocrine treatment. We can only get better at predicting this. Prognostic and predictive
432 biomarkers such as IL6ST will help stratify HR+/HER2+ tumours and identify which
433 treatment plan is best for each patient. We expect additional biomarkers and molecular
434 signatures for this subgroup to be identified soon, as well as better laboratory research
435 models developed and new breast cancer treatments and combinations of therapies
436 approved. Collectively, this will improve personalised care and outcome for this set of
437 patients.

438 **Executive summary**

439 **Hormone and targeted therapies for invasive breast cancer**

- 440 • Here we review hormone, HER2-targeted and other breast cancer treatments
441 currently available.

442 **Hormone therapy**

- 443 • Hormone receptor positive (HR+) cancers are dependent on oestrogen for
444 their growth and survival, so targeting this hormone, its signalling and its
445 downstream effects with hormone therapy is an important therapeutic
446 strategy.
- 447 • Tamoxifen, aromatase inhibitors and fulvestrant are hormone (also known as
448 endocrine or anti-oestrogen) therapies currently available for the treatment
449 of HR+ disease.

450 **HER2-targeted therapy**

- 451 • HER2-targeted therapies have significantly improved the prognosis and
452 outcome for patients with HER2+ breast cancer.
- 453 • Monoclonal antibodies trastuzumab and pertuzumab, tyrosine kinase
454 inhibitors lapatinib and neratinib and antibody-drug conjugates trastuzumab
455 emtansine (T-DM1) and trastuzumab deruxtecan are HER2-targeted
456 therapies currently available.

457 **Other targeted therapies for invasive breast cancer**

- 458 • CDK4/6 inhibitors induce cell cycle arrest, thereby stopping proliferation.
- 459 • Palbociclib, ribociclib and abemaciclib are CDK4/6 inhibitors currently
460 available for the treatment of HR+/HER2- breast cancer; not as much is
461 known about the utility of CDK inhibitors in HR+/HER2+ disease.

462 **Complications of the HR+/HER2+ subgroup**

- 463 • HR+/HER2+ tumours account for about 10% of all breast cancers, or about half of all
464 HER2+ tumours and have been shown to have a significantly worse prognosis
465 compared to other HR+ breast tumours.
- 466 • Combining hormone therapy with an anti-HER2 agent has proven beneficial to some
467 but not all HR+/HER2+ patients.

468 **Treating HR+/HER2+ breast cancer: What we've learned so far**

- 469 • Here we outline how patients with HR+/HER2+ tumours have been treated
470 historically and that these tumours should be treated as a distinct molecular subtype
471 of breast cancer.
- 472 • Previous clinical trials evaluating combined hormone and HER2-targeted therapies in
473 the neoadjuvant and adjuvant setting are discussed.

474 **Where we are now: current trials and emerging therapeutic strategies**

- 1
2
3 475 • Some HR+/HER2+ tumours behave more like the luminal A subtype (i.e., ER-driven
4 476 cancer) and others require a multipronged targeted blockade of the ER, PR and HER
5 477 pathways.
6
7 478 • Clinical trials with HR+/HER2+ patients currently underway are discussed; neratinib,
8 479 fulvestrant, palbociclib and T-DM1 show great promise alone and in various
9 480 combinations.

11 481 **Treatment resistance and HR/HER2 crosstalk**

- 13 482 • HR+/HER2+ tumours often respond initially to hormone therapy and/or HER2-
14 483 targeted therapy but develop resistance over time.
16 484 • The reason why some HR+/HER2+ cancers fail to respond to combined therapy or
17 485 become resistant to it remains unclear but evidence of ER and HER pathway
18 486 crosstalk, mutations in *ESR1* and *HER2*, lower *HER2* FISH ratio and activation of other
19 487 downstream pathways are likely to play a role.

21 488 **The need for a better understanding of the diverse biology of HR+/HER2+ and associated**
22 489 **biomarkers**

- 24 490 • Further investigation into the biology of HR+/HER2+ breast cancer is necessary in
25 491 order to have a clearer picture of how these tumours operate.
27 492 • Validated prognostic and predictive biomarkers are required to identify the patients
28 493 who will need combined endocrine/HER2 therapy and those who will need only
29 494 endocrine treatment.

31 495

33 496

497 **References**

- 498 1. Breast cancer statistics | World Cancer Research Fund. .
- 499 2. Qureshi A, Pervez S. Original Article Allred scoring for ER reporting and it ' s impact in
500 clearly distinguishing ER negative from ER positive breast cancers Study Population :
501 ER Immunohistochemical Analysis : *Am. J. Clin. Pathol.* 60(5), 350–353 (2010).
- 502 3. Kohler BA, Sherman RL, Howlader N, *et al.* Annual report to the nation on the status
503 of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity,
504 poverty, and state. *J. Natl. Cancer Inst.* 107(6) (2015).
- 505 4. McCann AH, Dervan PA, O'Regan M, *et al.* Prognostic Significance of c-
506 erbB-2 and Estrogen Receptor Status in Human Breast Cancer.
507 *Cancer Res.* 51(12), 3296 LP – 3303 (1991).
- 508 5. Peintinger F, Buzdar AU, Kuerer HM, *et al.* Hormone receptor status and pathologic
509 response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and
510 trastuzumab. *Ann. Oncol.* 19(12), 2020–2025 (2008).
- 511 6. Ross JS, Slodkowska EA, Symmans WF, Puzstai L, Ravdin PM, Hortobagyi GN. The
512 HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and
513 Personalized Medicine. *Oncologist.* 14(4), 320–368 (2009).
- 514 7. Perou CM, Sørli T, Eisen MB, *et al.* Molecular portraits of human breast tumours.
515 *letters to nature* 748. 533(May), 747–752 (2000).
- 516 8. Parker JSJS, Mullins M, Cheang MCU, *et al.* Supervised Risk Predictor of Breast Cancer
517 Based on Intrinsic Subtypes. *J. Clin. Oncol.* 27(8), 1160–1167 (2009).
- 518 9. Ward HWC. Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two
519 Dose Levels. *BMJ.* 1(5844), 13–14 (1973).
- 520 10. Nardone A, Weir H, Delpuech O, *et al.* The oral selective oestrogen receptor degrader
521 (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing
522 endocrine resistance. *Br. J. Cancer.* 120(3), 331–339 (2019).
- 523 11. McDonnell DP, Wardell SE, Norris JD. Oral Selective Estrogen Receptor
524 Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. *J.*
525 *Med. Chem.* 58(12), 4883–4887 (2015).
- 526 12. Hamilton EP, Patel MR, Armstrong AC, *et al.* A first-in-human study of the new oral
527 selective estrogen receptor degrader AZD9496 for ER+/HER2- advanced breast
528 cancer. *Clin. Cancer Res.* 24(15), 3510–3518 (2018).
- 529 13. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal
530 antibody, a novel agent for the treatment of metastatic breast cancer. *Clin. Ther.*
531 21(2), 309–318 (1999).
- 532 14. Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity:
533 current understanding, challenges, and frontiers. *Antib. Ther.* 1(1), 13–17 (2018).
- 534 15. Harbeck N, Beckmann MW, Rody A, *et al.* HER2 dimerization inhibitor pertuzumab -
535 Mode of action and clinical data in breast cancer. *Breast Care.* 8(1), 49–55 (2013).

- 1
2
3 536 16. Ryan Q, Ibrahim A, Cohen MH, *et al.* FDA Drug Approval Summary: Lapatinib in
4 537 Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That
5 538 Overexpresses HER-2. *Oncologist*. 13(10), 1114–1119 (2008).
- 7 539 17. Xu ZQ, Zhang Y, Li N, *et al.* Efficacy and safety of lapatinib and trastuzumab for HER2-
8 540 positive breast cancer: A systematic review and meta-analysis of randomised
9 541 controlled trials. *BMJ Open*. 7(3), 1–9 (2017).
- 12 542 18. Wang YC, Morrison G, Gillihan R, *et al.* Different mechanisms for resistance to
13 543 trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen
14 544 receptor and HER2 reactivation. *Breast Cancer Res*. 13(6), R121 (2011).
- 16 545 19. Overview | Neratinib for extended adjuvant treatment of hormone receptor-positive,
17 546 HER2-positive early stage breast cancer after adjuvant trastuzumab | Guidance |
18 547 NICE. NICE.
- 20 548 20. Lewis Phillips GD, Li G, Dugger DL, *et al.* Targeting HER2-positive breast cancer with
21 549 trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer Res*. 68(22), 9280–
22 550 9290 (2008).
- 25 551 21. Overview | Trastuzumab emtansine for treating HER2-positive advanced breast
26 552 cancer after trastuzumab and a taxane | Guidance | NICE. NICE.
- 28 553 22. Doi T, Shitara K, Naito Y, *et al.* Safety, pharmacokinetics, and antitumour activity of
29 554 trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in
30 555 patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1
31 556 dose-escalation study. *Lancet Oncol*. 18(11), 1512–1522 (2017).
- 33 557 23. Shah M, Nunes MR, Stearns V. CDK4/6 inhibitors: Game changers in the management
34 558 of hormone receptor– positive advanced breast cancer? *Oncol. (United States)*. 32(5),
35 559 216–222 (2018).
- 38 560 24. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. *Nat.*
39 561 *Rev. Clin. Oncol*. 13(7), 417–430 (2016).
- 41 562 25. Finn RS, Dering J, Conklin D, *et al.* PD 0332991, a selective cyclin D kinase 4/6
42 563 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive
43 564 human breast cancer cell lines in vitro. *Breast Cancer Res*. 11(5), R77 (2009).
- 45 565 26. Ding N hua, Liu C fan, Hu C, Yuan J qi, Liao W hua, Xiao Z. Prognostic Factors for
46 566 Luminal B-like Breast Cancer. *Curr. Med. Sci*. 39(3), 396–402 (2019).
- 48 567 27. Konecny G, Pauletti G, Pegram M, *et al.* Quantitative Association Between HER-2/neu
49 568 and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast
50 569 Cancer. *JNCI J. Natl. Cancer Inst*. 95(2), 142–153 (2003).
- 52 570 28. Howlader N, Altekruse SF, Li CI, *et al.* US incidence of breast cancer subtypes defined
53 571 by joint hormone receptor and HER2 status. *J. Natl. Cancer Inst*. 106(5) (2014).
- 55 572 29. Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive
56 573 breast cancer: Does estrogen receptor status define two distinct subtypes? *Ann.*
57 574 *Oncol*. 24(2), 283–291 (2013).
- 59
60

- 1
2
3 575 30. Arciero CA, Guo Y, Jiang R, *et al.* ER+/HER2+ Breast Cancer Has Different Metastatic
4 576 Patterns and Better Survival Than ER-/HER2+ Breast Cancer. *Clin. Breast Cancer.*
5 577 19(4), 236–245 (2019).
6
7 578 31. Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2
8 579 (her2)-positive and hormone receptor-positive breast cancer: New insights into
9 580 molecular interactions and clinical implications. *Ann. Oncol.* 24(11), 2715–2724
10 581 (2013).
11
12 582 32. Lønning PE. Poor-prognosis estrogen receptor- positive disease: Present and future
13 583 clinical solutions. *Ther. Adv. Med. Oncol.* 4(3), 127–137 (2012).
14
15 584 33. Montemurro F, Rossi V, Cossu Rocca M, *et al.* Hormone-receptor expression and
16 585 activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer
17 586 patients. *Cancer.* 118(1), 17–26 (2012).
18
19 587 34. Ellis MJ, Tao Y, Young O, *et al.* Estrogen-independent proliferation is present in
20 588 estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. *J.*
21 589 *Clin. Oncol.* 24(19), 3019–3025 (2006).
22
23 590 35. Shou J, Massarweh S, Osborne CK, *et al.* Mechanisms of tamoxifen resistance:
24 591 Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
25 592 *J. Natl. Cancer Inst.* 96(12), 926–935 (2004).
26
27 593 36. Wu VS, Kanaya N, Lo C, Mortimer J, Chen S. From bench to bedside: What do we
28 594 know about hormone receptor-positive and human epidermal growth factor receptor
29 595 2-positive breast cancer? *J. Steroid Biochem. Mol. Biol.* 153, 45–53 (2015).
30
31 596 37. Sengupta S, Schiff R, Katzenellenbogen BS. Post-transcriptional regulation of
32 597 chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-
33 598 positive breast cancer cells. *Breast Cancer Res. Treat.* 117(2), 243–251 (2009).
34
35 599 38. Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor
36 600 positive and human epidermal growth factor 2 positive breast cancers: Progress with
37 601 latest therapeutic strategies. *Ther. Adv. Med. Oncol.* 8(6), 429–449 (2016).
38
39 602 39. Nahta R, O’Regan RM. Therapeutic implications of estrogen receptor signaling in
40 603 HER2-positive breast cancers. *Breast Cancer Res. Treat.* 135(1), 39–48 (2012).
41
42 604 40. Giuliano M, Hu H, Wang Y-C, *et al.* Upregulation of ER Signaling as an Adaptive
43 605 Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2
44 606 Therapy. *Clin. Cancer Res.* 21(17), 3995 LP – 4003 (2015).
45
46 607 41. Sakai H, Tsurutani J, Iwasa T, *et al.* HER2 genomic amplification in circulating tumor
47 608 DNA and estrogen receptor positivity predict primary resistance to trastuzumab
48 609 emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. *Breast*
49 610 *Cancer.* 25(5), 605–613 (2018).
50
51 611 42. Robinson DR, Wu Y-M, Vats P, *et al.* Activating ESR1 mutations in hormone-resistant
52 612 metastatic breast cancer. *Nat. Genet.* 45(12), 1446–1451 (2013).
53
54 613 43. Xu X, De Angelis C, Burke KA, *et al.* HER2 Reactivation through Acquisition of the HER2
55 614 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in

- 1
2
3 615 HER2+ Breast Cancer. *Clin. Cancer Res.* 23(17), 5123 LP – 5134 (2017).
4
5 616 44. Nayar U, Cohen O, Kapstad C, *et al.* Acquired HER2 mutations in ER + metastatic
6 617 breast cancer confer resistance to estrogen receptor-directed therapies. *Nat. Genet.*
7 618 51(2), 207–216 (2019).
8
9 619 45. Martínez-Pérez C, Turnbull AK, Dixon JM. The evolving role of receptors as predictive
10 620 biomarkers for metastatic breast cancer. *Expert Rev. Anticancer Ther.* 19(2), 121–138
11 621 (2019).
12
13 622 46. García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine
14 623 therapy in breast cancer: Focus on signaling pathways, miRNAs and genetically based
15 624 resistance. *Int. J. Mol. Sci.* 14(1), 108–145 (2013).
16
17 625 47. Fribbens C, O’Leary B, Kilburn L, *et al.* Plasma ESR1 Mutations and the treatment of
18 626 estrogen receptor-Positive advanced breast cancer. *J. Clin. Oncol.* 34(25), 2961–2968
19 627 (2016).
20
21 628 48. Zhang K, Hong R, Xu F, *et al.* Clinical value of circulating ESR1 mutations for patients
22 629 with metastatic breast cancer: a meta-analysis. *Cancer Manag. Res.* 10, 2573 (2018).
23
24 630 49. Allouchery V, Beaussire L, Perdrix A, *et al.* Circulating ESR1 mutations at the end of
25 631 aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
26 632 *Breast Cancer Res.* 20(1), 1–5 (2018).
27
28 633 50. Yan C, Wei H, Minjuan Z, *et al.* The mTOR inhibitor rapamycin synergizes with a fatty
29 634 acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
30 635 *PLoS One.* 9(5), 1–12 (2014).
31
32 636 51. McDermott MSJ, Canonici A, Ivers L, *et al.* Dual inhibition of IGF1R and ER enhances
33 637 response to trastuzumab in HER2 positive breast cancer cells. *Int. J. Oncol.* 50(6),
34 638 2221–2228 (2017).
35
36 639 52. Thaler S, Schmidt M, Thiede G, Schad A, Sleeman J. Abstract P6-12-14: Proteasome
37 640 inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell
38 641 death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. 8(42), P6-
39 642 12-14-P6-12–14 (2017).
40
41 643 53. McKenna M, McGarrigle S, Pidgeon GP. The next generation of PI3K-Akt-mTOR
42 644 pathway inhibitors in breast cancer cohorts. *Biochim. Biophys. Acta - Rev. Cancer.*
43 645 1870(2), 185–197 (2018).
44
45 646 54. Lowenfeld L, Zaheer S, Oechsle C, *et al.* Addition of anti-estrogen therapy to anti-
46 647 HER2 dendritic cell vaccination improves regional nodal immune response and
47 648 pathologic complete response rate in patients with ERpos/HER2pos early breast
48 649 cancer. *Oncoimmunology.* 6(9), 1–12 (2017).
49
50 650 55. Kulkoyluoglu-Cotul E, Arca A, Madak-Erdogan Z. Crosstalk between Estrogen Signaling
51 651 and Breast Cancer Metabolism. *Trends Endocrinol. Metab.* 30(1), 25–38 (2019).
52
53 652 56. Turnbull AK, Arthur LM, Renshaw L, *et al.* Accurate Prediction and Validation of
54 653 Response to Endocrine Therapy in Breast Cancer. *J. Clin. Oncol.* 33(20), 2270–8
55 654 (2015).
56
57
58
59
60

- 1
2
3 655 57. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin).
4 656 *Endocr. Relat. Cancer.* 9(2), 75–85 (2002).
- 6 657 58. Tripathy D, Kaufman PA, Brufsky AM, *et al.* First-Line Treatment Patterns and Clinical
7 658 Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic
8 659 Breast Cancer From registHER. *Oncologist.* 18(5), 501–510 (2013).
- 10 660 59. Gradishar WJ, Anderson BO, Balassanian R, *et al.* NCCN Guidelines® insights breast
11 661 cancer, version 1.2017: Featured updates to the NCCN Guidelines. *JNCCN J. Natl.*
12 662 *Compr. Cancer Netw.* 15(4), 433–451 (2017).
- 15 663 60. Statler AB, Hobbs BP, Wei W, Gupta A, Blake CN, Nahleh ZA. Real-world Treatment
16 664 Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National
17 665 Cancer Database Analysis. *Sci. Rep.* 9(1), 1–10 (2019).
- 19 666 61. Vici P, Pizzuti L, Natoli C, *et al.* Triple positive breast cancer: A distinct subtype?
20 667 *Cancer Treat. Rev.* 41(2), 69–76 (2015).
- 22 668 62. You SH, Chae BJ, Eom YH, *et al.* Clinical differences in triple-positive operable breast
23 669 cancer subtypes in Korean patients: An analysis of Korean breast cancer registry data.
24 670 *J. Breast Cancer.* 21(4), 415–424 (2018).
- 26 671 63. Kaufman B, Mackey JR, Clemens MR, *et al.* Trastuzumab plus anastrozole versus
27 672 anastrozole alone for the treatment of postmenopausal women with human
28 673 epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic
29 674 breast cancer: Results from the randomized phase III TAnDEM study. *J. Clin. Oncol.*
30 675 27(33), 5529–5537 (2009).
- 33 676 64. Huober J, Fasching PA, Barsoum M, *et al.* Higher efficacy of letrozole in combination
34 677 with trastuzumab compared to letrozole monotherapy as first-line treatment in
35 678 patients with HER2-positive, hormone-receptor-positive metastatic breast cancer -
36 679 Results of the eLEcTRA trial. *Breast.* 21(1), 27–33 (2012).
- 39 680 65. Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L. Hormone
40 681 Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where
41 682 we are now and where we are going. *Cancer Treat. Rev.* 46, 20–26 (2016).
- 43 683 66. Roche PC, Suman VJ, Jenkins RB, *et al.* Concordance between local and central
44 684 laboratory HER2 testing in the breast intergroup trial N9831. *J. Natl. Cancer Inst.*
45 685 94(11), 855–857 (2002).
- 47 686 67. Rosa M, Khazai L. Comparison of HER2 testing among laboratories: Our experience
48 687 with review cases retested at Moffitt Cancer Center in a two-year period. *Breast J.*
49 688 24(2), 139–147 (2018).
- 52 689 68. Prat A, Cheang MCU, Galván P, *et al.* Prognostic Value of Intrinsic Subtypes in
53 690 Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or
54 691 Without Lapatinib. *JAMA Oncol.* 2(10), 1287–1294 (2016).
- 56 692 69. Viale G, Munzone E. Treatment selection for patients with equivocal HER2 status and
57 693 in luminal versus HER2-enriched disease. *Breast.* 48, S49–S52 (2019).
- 59 694 70. Swain SM, Baselga J, Kim S-B, *et al.* Pertuzumab, Trastuzumab, and Docetaxel in

- 1
2
3 695 HER2-Positive Metastatic Breast Cancer. *N. Engl. J. Med.* 372(8), 724–734 (2015).
4
5 696 71. Overview | Pertuzumab with trastuzumab and docetaxel for treating HER2-positive
6 697 breast cancer | Guidance | NICE. NICE.
7
8 698 72. Overview | Pertuzumab for the neoadjuvant treatment of HER2-positive breast
9 699 cancer | Guidance | NICE. NICE.
10
11 700 73. Berry DA, Ph D, Cirrincione C, *et al.* NIH Public Access. 295(14), 1658–1667 (2006).
12
13 701 74. Wapnir IL, Price KN, Anderson SJ, *et al.* Efficacy of chemotherapy for ER-negative and
14 702 ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the
15 703 CALOR trial. *J. Clin. Oncol.* 36(11), 1073–1079 (2018).
16
17 704 75. Saleh RR, Bouganim N, Hilton J, Arnaout A, Clemons M. Neoadjuvant endocrine
18 705 treatment for breast cancer: from bedside to bench and back again? *Curr. Oncol.*
19 706 21(1), e122–e128 (2014).
20
21
22 707 76. Miller WR, Larionov AA, Renshaw L, *et al.* Changes in breast cancer transcriptional
23 708 profiles after treatment with the aromatase inhibitor, letrozole. *Pharmacogenet.*
24 709 *Genomics.* 17(10), 813–826 (2007).
25
26 710 77. Dixon JM. Does presurgical treatment destroy important prognostic information.
27 711 *Breast Cancer Res.* 9(S2), 9–11 (2007).
28
29 712 78. Di Cosimo S, Arpino G, Generali D. Neoadjuvant treatment of HER2 and hormone-
30 713 receptor positive breast cancer - Moving beyond pathological complete response.
31 714 *Breast.* 23(2), 188–192 (2014).
32
33 715 79. Gianni L, Bisagni G, Colleoni M, *et al.* Neoadjuvant treatment with trastuzumab and
34 716 pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast
35 717 cancer (NA-PHER2): an exploratory, open-label, phase 2 study. *Lancet Oncol.* 19(2),
36 718 249–256 (2018).
37
38
39 719 80. Chow LWC, Morita S, Chow CYC, Ng WK, Toi M. Neoadjuvant palbociclib on ER+
40 720 breast cancer (N007): Clinical response and EndoPredict's value. *Endocr. Relat.*
41 721 *Cancer.* 25(2), 123–130 (2018).
42
43
44 722 81. Risi E, Grilli A, Migliaccio I, *et al.* A gene expression signature of Retinoblastoma loss-
45 723 of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-
46 724 positive breast cancer patients. *Breast Cancer Res. Treat.* 170(2), 329–341 (2018).
47
48 725 82. Brodsky AS, Xiong J, Yang D, *et al.* Identification of stromal ColXa1 and tumor-
49 726 infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in
50 727 estrogen receptor-positive/HER2-positive breast cancer. *BMC Cancer.* 16(1), 1–13
51 728 (2016).
52
53 729 83. Rimawi M, Ferrero JM, De La Haba-Rodriguez J, *et al.* First-line trastuzumab plus an
54 730 aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor
55 731 receptor 2-positive and hormone receptor-positive metastatic or locally advanced
56 732 breast cancer (PERTAIN): A randomized, open-label phase II tr. *J. Clin. Oncol.* 36(28),
57 733 2826–2835 (2018).
58
59
60

- 1
2
3 734 84. Ruz O, Kószó R, Dobi Á, *et al.* Clinical benefit of fulvestrant monotherapy in the
4 735 multimodal treatment of hormone receptor and HER2 positive advanced breast
5 736 cancer: A case series. *Onco. Targets. Ther.* 11, 5459–5463 (2018).
- 7 737 85. Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer - Full Text View -
8 738 ClinicalTrials.gov. .
- 10 739 86. Smyth LM, Saura C, Piha-Paul SA, *et al.* Update on the phase II SUMMIT trial:
11 740 Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer. *Ann.*
12 741 *Oncol.* 30(May), iii10–iii11 (2019).
- 15 742 87. Turner NC, Ro J, André F, *et al.* Palbociclib in hormone-receptor-positive advanced
16 743 breast cancer. *N. Engl. J. Med.* 373(3), 209–219 (2015).
- 18 744 88. O’leary B, Cutts RJ, Liu Y, *et al.* The genetic landscape and clonal evolution of breast
19 745 cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. *Cancer Discov.*
20 746 8(11), 1390–1403 (2018).
- 22 747 89. Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor
23 748 Receptor 2 Positive (HER2+) Metastatic Breast Cancer - Full Text View -
24 749 ClinicalTrials.gov. .
- 26 750 90. Tolaney SM, Wardley AM, Zambelli S, *et al.* Abemaciclib plus trastuzumab with or
27 751 without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in
28 752 women with hormone receptor-positive, HER2-positive advanced breast cancer
29 753 (monarchER): a randomised, open-label, phase 2 trial. *Lancet Oncol.* 21(6), 763–775
30 754 (2020).
- 33 755 91. Johnston SRD, Hegg R, Im S-A, *et al.* Phase III, Randomized Study of Dual Human
34 756 Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus
35 757 Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal
36 758 Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast. *J. Clin.*
37 759 *Oncol.* , JCO.20.01894 (2020).
- 40 760 92. Park JH, Kang MJ, Ahn JH, *et al.* Phase II trial of neoadjuvant letrozole and lapatinib in
41 761 Asian postmenopausal women with estrogen receptor (ER) and human epidermal
42 762 growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the
43 763 TILs, ER expressional change after ne. *Cancer Chemother. Pharmacol.* 78(4), 685–695
44 764 (2016).
- 47 765 93. Rimawi M, Cecchini R, Rastogi P, *et al.* Abstract S3-06: A phase III trial evaluating pCR
48 766 in patients with HR+, HER2-positive breast cancer treated with neoadjuvant
49 767 docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen
50 768 deprivation: NRG Oncology/NSABP B-52. In: *General Session Abstracts*, American
51 769 Association for Cancer Research, S3-06-S3-06 (2017).
- 53 770 94. Martin M, Holmes FA, Ejlersen B, *et al.* Neratinib after trastuzumab-based adjuvant
54 771 therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised,
55 772 double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 18(12), 1688–1700
56 773 (2017).
- 59 774 95. Schwarz LJ, Croessmann SE, Avogadri-Connors F, Cutler RE, Lalani AS, Arteaga CL.

- 1
2
3 775 Abstract 4818: Neratinib/fulvestrant but not fulvestrant alone maintain complete
4 776 responses after treatment with trastuzumab/paclitaxel of mice bearing ER+/HER2+
5 777 xenografts. *Cancer Res.* 77(13 Supplement), 4818 LP – 4818 (2017).
- 6
7 778 96. Sudhan DR, Schwarz LJ, Guerrero-Zotano A, *et al.* Extended adjuvant therapy with
8 779 neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete
9 780 responses of ER β /HER2 β breast cancers: Implications to the EXTENET trial. *Clin.*
10 781 *Cancer Res.* 25(2), 771–783 (2019).
- 11
12
13 782 97. Chong QY, You ML, Pandey V, *et al.* Release of HER2 repression of trefoil factor 3
14 783 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary
15 784 carcinoma. *Oncotarget.* 8(43), 74188–74208 (2017).
- 16
17 785 98. Turnbull AK, Webber V, McStay D, *et al.* Abstract P1-18-07: Can some ER+/HER2+
18 786 patients be safely spared from treatment with chemotherapy plus herceptin? *Cancer*
19 787 *Res.* 80(4 Supplement), P1-18-07 LP-P1-18-07 (2020).
- 20
21
22 788 99. Kanaya N, Somlo G, Wu J, *et al.* Characterization of patient-derived tumor xenografts
23 789 (PDXs) as models for estrogen receptor positive (ER+HER2– and ER+HER2+) breast
24 790 cancers. *J. Steroid Biochem. Mol. Biol.* 170, 65–74 (2017).
- 25
26 791 1. Breast cancer statistics | World Cancer Research Fund. .
- 27
28 792 2. Qureshi A, Pervez S. Original Article Allred scoring for ER reporting and it ' s impact in
29 793 clearly distinguishing ER negative from ER positive breast cancers Study Population :
30 794 ER Immunohistochemical Analysis : *Am. J. Clin. Pathol.* 60(5), 350–353 (2010).
- 31
32 795 3. Kohler BA, Sherman RL, Howlader N, *et al.* Annual report to the nation on the status
33 796 of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity,
34 797 poverty, and state. *J. Natl. Cancer Inst.* 107(6) (2015).
- 35
36 798 4. McCann AH, Dervan PA, O'Regan M, *et al.* Prognostic Significance of c-
37 799 erbB-2 and Estrogen Receptor Status in Human Breast Cancer.
38 800 *Cancer Res.* 51(12), 3296 LP – 3303 (1991).
- 39
40
41 801 5. Peintinger F, Buzdar AU, Kuerer HM, *et al.* Hormone receptor status and pathologic
42 802 response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and
43 803 trastuzumab. *Ann. Oncol.* 19(12), 2020–2025 (2008).
- 44
45 804 6. Ross JS, Slodkowska EA, Symmans WF, Puzstai L, Ravdin PM, Hortobagyi GN. The
46 805 HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and
47 806 Personalized Medicine. *Oncologist.* 14(4), 320–368 (2009).
- 48
49 807 7. Perou CM, Sørli T, Eisen MB, *et al.* Molecular portraits of human breast tumours.
50 808 *letters to nature* 748. 533(May), 747–752 (2000).
- 51
52
53 809 8. Parker JSJS, Mullins M, Cheang MCU, *et al.* Supervised Risk Predictor of Breast Cancer
54 810 Based on Intrinsic Subtypes. *J. Clin. Oncol.* 27(8), 1160–1167 (2009).
- 55
56 811 9. Ward HWC. Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two
57 812 Dose Levels. *BMJ.* 1(5844), 13–14 (1973).
- 58
59 813 10. Nardone A, Weir H, Delpuech O, *et al.* The oral selective oestrogen receptor degrader
60

- 1
2
3 814 (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing
4 815 endocrine resistance. *Br. J. Cancer*. 120(3), 331–339 (2019).
- 6 816 11. McDonnell DP, Wardell SE, Norris JD. Oral Selective Estrogen Receptor
7 817 Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. *J.*
8 818 *Med. Chem.* 58(12), 4883–4887 (2015).
- 10 819 12. Hamilton EP, Patel MR, Armstrong AC, *et al.* A first-in-human study of the new oral
11 820 selective estrogen receptor degrader AZD9496 for ER+/HER2- advanced breast
12 821 cancer. *Clin. Cancer Res.* 24(15), 3510–3518 (2018).
- 15 822 13. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal
16 823 antibody, a novel agent for the treatment of metastatic breast cancer. *Clin. Ther.*
17 824 21(2), 309–318 (1999).
- 19 825 14. Mohan N, Jiang J, Dokmanovic M, Wu WJ. Trastuzumab-mediated cardiotoxicity:
20 826 current understanding, challenges, and frontiers. *Antib. Ther.* 1(1), 13–17 (2018).
- 22 827 15. Harbeck N, Beckmann MW, Rody A, *et al.* HER2 dimerization inhibitor pertuzumab -
23 828 Mode of action and clinical data in breast cancer. *Breast Care*. 8(1), 49–55 (2013).
- 25 829 16. Ryan Q, Ibrahim A, Cohen MH, *et al.* FDA Drug Approval Summary: Lapatinib in
26 830 Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That
27 831 Overexpresses HER-2. *Oncologist*. 13(10), 1114–1119 (2008).
- 30 832 17. Xu ZQ, Zhang Y, Li N, *et al.* Efficacy and safety of lapatinib and trastuzumab for HER2-
31 833 positive breast cancer: A systematic review and meta-analysis of randomised
32 834 controlled trials. *BMJ Open*. 7(3), 1–9 (2017).
- 34 835 18. Wang YC, Morrison G, Gillihan R, *et al.* Different mechanisms for resistance to
35 836 trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen
36 837 receptor and HER2 reactivation. *Breast Cancer Res.* 13(6), R121 (2011).
- 38 838 19. Overview | Neratinib for extended adjuvant treatment of hormone receptor-positive,
39 839 HER2-positive early stage breast cancer after adjuvant trastuzumab | Guidance |
40 840 NICE. NICE.
- 43 841 20. Lewis Phillips GD, Li G, Dugger DL, *et al.* Targeting HER2-positive breast cancer with
44 842 trastuzumab-DM1, an antibody-cytotoxic drug conjugate. *Cancer Res.* 68(22), 9280–
45 843 9290 (2008).
- 47 844 21. Overview | Trastuzumab emtansine for treating HER2-positive advanced breast
48 845 cancer after trastuzumab and a taxane | Guidance | NICE. NICE.
- 50 846 22. Doi T, Shitara K, Naito Y, *et al.* Safety, pharmacokinetics, and antitumour activity of
51 847 trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in
52 848 patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1
53 849 dose-escalation study. *Lancet Oncol.* 18(11), 1512–1522 (2017).
- 56 850 23. Shah M, Nunes MR, Stearns V. CDK4/6 inhibitors: Game changers in the management
57 851 of hormone receptor– positive advanced breast cancer? *Oncol. (United States)*. 32(5),
58 852 216–222 (2018).
- 59
60

- 1
2
3 853 24. O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. *Nat. Rev. Clin. Oncol.* 13(7), 417–430 (2016).
4 854
5
6 855 25. Finn RS, Dering J, Conklin D, *et al.* PD 0332991, a selective cyclin D kinase 4/6
7 856 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive
8 857 human breast cancer cell lines in vitro. *Breast Cancer Res.* 11(5), R77 (2009).
9
10 858 26. Ding N hua, Liu C fan, Hu C, Yuan J qi, Liao W hua, Xiao Z. Prognostic Factors for
11 859 Luminal B-like Breast Cancer. *Curr. Med. Sci.* 39(3), 396–402 (2019).
12
13 860 27. Konecny G, Pauletti G, Pegram M, *et al.* Quantitative Association Between HER-2/neu
14 861 and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast
15 862 Cancer. *JNCI J. Natl. Cancer Inst.* 95(2), 142–153 (2003).
16
17 863 28. Howlader N, Altekruse SF, Li CI, *et al.* US incidence of breast cancer subtypes defined
18 864 by joint hormone receptor and HER2 status. *J. Natl. Cancer Inst.* 106(5) (2014).
19
20 865 29. Vaz-Luis I, Winer EP, Lin NU. Human epidermal growth factor receptor-2-positive
21 866 breast cancer: Does estrogen receptor status define two distinct subtypes? *Ann.*
22 867 *Oncol.* 24(2), 283–291 (2013).
23
24 868 30. Arciero CA, Guo Y, Jiang R, *et al.* ER+/HER2+ Breast Cancer Has Different Metastatic
25 869 Patterns and Better Survival Than ER–/HER2+ Breast Cancer. *Clin. Breast Cancer.*
26 870 19(4), 236–245 (2019).
27
28 871 31. Montemurro F, Di Cosimo S, Arpino G. Human epidermal growth factor receptor 2
29 872 (her2)-positive and hormone receptor-positive breast cancer: New insights into
30 873 molecular interactions and clinical implications. *Ann. Oncol.* 24(11), 2715–2724
31 874 (2013).
32
33 875 32. Lønning PE. Poor-prognosis estrogen receptor- positive disease: Present and future
34 876 clinical solutions. *Ther. Adv. Med. Oncol.* 4(3), 127–137 (2012).
35
36 877 33. Montemurro F, Rossi V, Cossu Rocca M, *et al.* Hormone-receptor expression and
37 878 activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer
38 879 patients. *Cancer.* 118(1), 17–26 (2012).
39
40 880 34. Ellis MJ, Tao Y, Young O, *et al.* Estrogen-independent proliferation is present in
41 881 estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. *J.*
42 882 *Clin. Oncol.* 24(19), 3019–3025 (2006).
43
44 883 35. Shou J, Massarweh S, Osborne CK, *et al.* Mechanisms of tamoxifen resistance:
45 884 Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
46 885 *J. Natl. Cancer Inst.* 96(12), 926–935 (2004).
47
48 886 36. Wu VS, Kanaya N, Lo C, Mortimer J, Chen S. From bench to bedside: What do we
49 887 know about hormone receptor-positive and human epidermal growth factor receptor
50 888 2-positive breast cancer? *J. Steroid Biochem. Mol. Biol.* 153, 45–53 (2015).
51
52 889 37. Sengupta S, Schiff R, Katzenellenbogen BS. Post-transcriptional regulation of
53 890 chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-
54 891 positive breast cancer cells. *Breast Cancer Res. Treat.* 117(2), 243–251 (2009).
55
56
57
58
59
60

- 1
2
3 892 38. Lousberg L, Collignon J, Jerusalem G. Resistance to therapy in estrogen receptor
4 893 positive and human epidermal growth factor 2 positive breast cancers: Progress with
5 894 latest therapeutic strategies. *Ther. Adv. Med. Oncol.* 8(6), 429–449 (2016).
- 7 895 39. Nahta R, O'Regan RM. Therapeutic implications of estrogen receptor signaling in
8 896 HER2-positive breast cancers. *Breast Cancer Res. Treat.* 135(1), 39–48 (2012).
- 10 897 40. Giuliano M, Hu H, Wang Y-C, *et al.* Upregulation of ER Signaling as an Adaptive
11 898 Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2
12 899 Therapy. *Clin. Cancer Res.* 21(17), 3995 LP – 4003 (2015).
- 15 900 41. Sakai H, Tsurutani J, Iwasa T, *et al.* HER2 genomic amplification in circulating tumor
16 901 DNA and estrogen receptor positivity predict primary resistance to trastuzumab
17 902 emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. *Breast*
18 903 *Cancer.* 25(5), 605–613 (2018).
- 20 904 42. Robinson DR, Wu Y-M, Vats P, *et al.* Activating ESR1 mutations in hormone-resistant
21 905 metastatic breast cancer. *Nat. Genet.* 45(12), 1446–1451 (2013).
- 23 906 43. Xu X, De Angelis C, Burke KA, *et al.* HER2 Reactivation through Acquisition of the HER2
24 907 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in
25 908 HER2+ Breast Cancer. *Clin. Cancer Res.* 23(17), 5123 LP – 5134 (2017).
- 28 909 44. Nayar U, Cohen O, Kapstad C, *et al.* Acquired HER2 mutations in ER + metastatic
29 910 breast cancer confer resistance to estrogen receptor-directed therapies. *Nat. Genet.*
30 911 51(2), 207–216 (2019).
- 32 912 45. Martínez-Pérez C, Turnbull AK, Dixon JM. The evolving role of receptors as predictive
33 913 biomarkers for metastatic breast cancer. *Expert Rev. Anticancer Ther.* 19(2), 121–138
34 914 (2019).
- 36 915 46. García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine
37 916 therapy in breast cancer: Focus on signaling pathways, miRNAs and genetically based
38 917 resistance. *Int. J. Mol. Sci.* 14(1), 108–145 (2013).
- 41 918 47. Fribbens C, O'Leary B, Kilburn L, *et al.* Plasma ESR1 Mutations and the treatment of
42 919 estrogen receptor-Positive advanced breast cancer. *J. Clin. Oncol.* 34(25), 2961–2968
43 920 (2016).
- 45 921 48. Zhang K, Hong R, Xu F, *et al.* Clinical value of circulating ESR1 mutations for patients
46 922 with metastatic breast cancer: a meta-analysis. *Cancer Manag. Res.* 10, 2573 (2018).
- 48 923 49. Allouchery V, Beaussire L, Perdrix A, *et al.* Circulating ESR1 mutations at the end of
49 924 aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients.
50 925 *Breast Cancer Res.* 20(1), 1–5 (2018).
- 52 926 50. Yan C, Wei H, Minjuan Z, *et al.* The mTOR inhibitor rapamycin synergizes with a fatty
53 927 acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
54 928 *PLoS One.* 9(5), 1–12 (2014).
- 57 929 51. McDermott MSJ, Canonici A, Ivers L, *et al.* Dual inhibition of IGF1R and ER enhances
58 930 response to trastuzumab in HER2 positive breast cancer cells. *Int. J. Oncol.* 50(6),
59 931 2221–2228 (2017).

- 1
2
3 932 52. Thaler S, Schmidt M, Thiede G, Schad A, Sleeman J. Abstract P6-12-14: Proteasome
4 933 inhibitors prevent bi-directional HER2/estrogen-receptor cross-talk leading to cell
5 934 death in endocrine and lapatinib-resistant HER2+/ER+ breast cancer cells. 8(42), P6-
6 935 12-14-P6-12–14 (2017).
7
8
9 936 53. McKenna M, McGarrigle S, Pidgeon GP. The next generation of PI3K-Akt-mTOR
10 937 pathway inhibitors in breast cancer cohorts. *Biochim. Biophys. Acta - Rev. Cancer.*
11 938 1870(2), 185–197 (2018).
12
13 939 54. Lowenfeld L, Zaheer S, Oechsle C, *et al.* Addition of anti-estrogen therapy to anti-
14 940 HER2 dendritic cell vaccination improves regional nodal immune response and
15 941 pathologic complete response rate in patients with ERpos/HER2pos early breast
16 942 cancer. *Oncoimmunology.* 6(9), 1–12 (2017).
17
18 943 55. Kulkoyluoglu-Cotul E, Arca A, Madak-Erdogan Z. Crosstalk between Estrogen Signaling
19 944 and Breast Cancer Metabolism. *Trends Endocrinol. Metab.* 30(1), 25–38 (2019).
20
21 945 56. Turnbull AK, Arthur LM, Renshaw L, *et al.* Accurate Prediction and Validation of
22 946 Response to Endocrine Therapy in Breast Cancer. *J. Clin. Oncol.* 33(20), 2270–8
23 947 (2015).
24
25 948 57. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin).
26 949 *Endocr. Relat. Cancer.* 9(2), 75–85 (2002).
27
28 950 58. Tripathy D, Kaufman PA, Brufsky AM, *et al.* First-Line Treatment Patterns and Clinical
29 951 Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic
30 952 Breast Cancer From registHER. *Oncologist.* 18(5), 501–510 (2013).
31
32 953 59. Gradishar WJ, Anderson BO, Balassanian R, *et al.* NCCN Guidelines® insights breast
33 954 cancer, version 1.2017: Featured updates to the NCCN Guidelines. *JNCCN J. Natl.*
34 955 *Compr. Cancer Netw.* 15(4), 433–451 (2017).
35
36 956 60. Statler AB, Hobbs BP, Wei W, Gupta A, Blake CN, Nahleh ZA. Real-world Treatment
37 957 Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National
38 958 Cancer Database Analysis. *Sci. Rep.* 9(1), 1–10 (2019).
39
40 959 61. Vici P, Pizzuti L, Natoli C, *et al.* Triple positive breast cancer: A distinct subtype?
41 960 *Cancer Treat. Rev.* 41(2), 69–76 (2015).
42
43 961 62. You SH, Chae BJ, Eom YH, *et al.* Clinical differences in triple-positive operable breast
44 962 cancer subtypes in Korean patients: An analysis of Korean breast cancer registry data.
45 963 *J. Breast Cancer.* 21(4), 415–424 (2018).
46
47 964 63. Kaufman B, Mackey JR, Clemens MR, *et al.* Trastuzumab plus anastrozole versus
48 965 anastrozole alone for the treatment of postmenopausal women with human
49 966 epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic
50 967 breast cancer: Results from the randomized phase III TAnDEM study. *J. Clin. Oncol.*
51 968 27(33), 5529–5537 (2009).
52
53 969 64. Huober J, Fasching PA, Barsoum M, *et al.* Higher efficacy of letrozole in combination
54 970 with trastuzumab compared to letrozole monotherapy as first-line treatment in
55 971 patients with HER2-positive, hormone-receptor-positive metastatic breast cancer -
56 972 Results of the eLEcTRA trial. *Breast.* 21(1), 27–33 (2012).

- 1
2
3 973 65. Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L. Hormone
4 974 Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where
5 975 we are now and where we are going. *Cancer Treat. Rev.* 46, 20–26 (2016).
- 6
7 976 66. Roche PC, Suman VJ, Jenkins RB, *et al.* Concordance between local and central
8 977 laboratory HER2 testing in the breast intergroup trial N9831. *J. Natl. Cancer Inst.*
9 978 94(11), 855–857 (2002).
- 10
11
12 979 67. Rosa M, Khazai L. Comparison of HER2 testing among laboratories: Our experience
13 980 with review cases retested at Moffitt Cancer Center in a two-year period. *Breast J.*
14 981 24(2), 139–147 (2018).
- 15
16 982 68. Prat A, Cheang MCU, Galván P, *et al.* Prognostic Value of Intrinsic Subtypes in
17 983 Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or
18 984 Without Lapatinib. *JAMA Oncol.* 2(10), 1287–1294 (2016).
- 19
20 985 69. Viale G, Munzone E. Treatment selection for patients with equivocal HER2 status and
21 986 in luminal versus HER2-enriched disease. *Breast.* 48, S49–S52 (2019).
- 22
23
24 987 70. Swain SM, Baselga J, Kim S-B, *et al.* Pertuzumab, Trastuzumab, and Docetaxel in
25 988 HER2-Positive Metastatic Breast Cancer. *N. Engl. J. Med.* 372(8), 724–734 (2015).
- 26
27 989 71. Overview | Pertuzumab with trastuzumab and docetaxel for treating HER2-positive
28 990 breast cancer | Guidance | NICE. NICE.
- 29
30 991 72. Overview | Pertuzumab for the neoadjuvant treatment of HER2-positive breast
31 992 cancer | Guidance | NICE. NICE.
- 32
33 993 73. Berry DA, Ph D, Cirrincione C, *et al.* NIH Public Access. 295(14), 1658–1667 (2006).
- 34
35 994 74. Wapnir IL, Price KN, Anderson SJ, *et al.* Efficacy of chemotherapy for ER-negative and
36 995 ER-positive isolated locoregional recurrence of breast cancer: Final analysis of the
37 996 CALOR trial. *J. Clin. Oncol.* 36(11), 1073–1079 (2018).
- 38
39 997 75. Saleh RR, Bouganim N, Hilton J, Arnaout A, Clemons M. Neoadjuvant endocrine
40 998 treatment for breast cancer: from bedside to bench and back again? *Curr. Oncol.*
41 999 21(1), e122–e128 (2014).
- 42
43 1000 76. Miller WR, Larionov AA, Renshaw L, *et al.* Changes in breast cancer transcriptional
44 1001 profiles after treatment with the aromatase inhibitor, letrozole. *Pharmacogenet.*
45 1002 *Genomics.* 17(10), 813–826 (2007).
- 46
47
48 1003 77. Dixon JM. Does presurgical treatment destroy important prognostic information.
49 1004 *Breast Cancer Res.* 9(S2), 9–11 (2007).
- 50
51 1005 78. Di Cosimo S, Arpino G, Generali D. Neoadjuvant treatment of HER2 and hormone-
52 1006 receptor positive breast cancer - Moving beyond pathological complete response.
53 1007 *Breast.* 23(2), 188–192 (2014).
- 54
55 1008 79. Gianni L, Bisagni G, Colleoni M, *et al.* Neoadjuvant treatment with trastuzumab and
56 1009 pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast
57 1010 cancer (NA-PHER2): an exploratory, open-label, phase 2 study. *Lancet Oncol.* 19(2),
58 1011 249–256 (2018).
- 59
60

- 1
2
3 1012 80. Chow LWC, Morita S, Chow CYC, Ng WK, Toi M. Neoadjuvant palbociclib on ER+
4 1013 breast cancer (N007): Clinical response and EndoPredict's value. *Endocr. Relat.*
5 1014 *Cancer*. 25(2), 123–130 (2018).
6
7 1015 81. Risi E, Grilli A, Migliaccio I, *et al.* A gene expression signature of Retinoblastoma loss-
8 1016 of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-
9 1017 positive breast cancer patients. *Breast Cancer Res. Treat.* 170(2), 329–341 (2018).
10
11 1018 82. Brodsky AS, Xiong J, Yang D, *et al.* Identification of stromal ColXa1 and tumor-
12 1019 infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in
13 1020 estrogen receptor-positive/HER2-positive breast cancer. *BMC Cancer*. 16(1), 1–13
14 1021 (2016).
15
16 1022 83. Rimawi M, Ferrero JM, De La Haba-Rodriguez J, *et al.* First-line trastuzumab plus an
17 1023 aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor
18 1024 receptor 2-positive and hormone receptor-positive metastatic or locally advanced
19 1025 breast cancer (PERTAIN): A randomized, open-label phase II tr. *J. Clin. Oncol.* 36(28),
20 1026 2826–2835 (2018).
21
22 1027 84. Ruz O, Kószó R, Dobi Á, *et al.* Clinical benefit of fulvestrant monotherapy in the
23 1028 multimodal treatment of hormone receptor and HER2 positive advanced breast
24 1029 cancer: A case series. *Onco. Targets. Ther.* 11, 5459–5463 (2018).
25
26 1030 85. Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer - Full Text View -
27 1031 ClinicalTrials.gov. .
28
29 1032 86. Smyth LM, Saura C, Piha-Paul SA, *et al.* Update on the phase II SUMMIT trial:
30 1033 Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer. *Ann.*
31 1034 *Oncol.* 30(May), iii10–iii11 (2019).
32
33 1035 87. Turner NC, Ro J, André F, *et al.* Palbociclib in hormone-receptor-positive advanced
34 1036 breast cancer. *N. Engl. J. Med.* 373(3), 209–219 (2015).
35
36 1037 88. O'leary B, Cutts RJ, Liu Y, *et al.* The genetic landscape and clonal evolution of breast
37 1038 cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. *Cancer Discov.*
38 1039 8(11), 1390–1403 (2018).
39
40 1040 89. Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor
41 1041 Receptor 2 Positive (HER2+) Metastatic Breast Cancer - Full Text View -
42 1042 ClinicalTrials.gov. .
43
44 1043 90. Tolaney SM, Wardley AM, Zambelli S, *et al.* Abemaciclib plus trastuzumab with or
45 1044 without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in
46 1045 women with hormone receptor-positive, HER2-positive advanced breast cancer
47 1046 (monarchER): a randomised, open-label, phase 2 trial. *Lancet Oncol.* 21(6), 763–775
48 1047 (2020).
49
50 1048 91. Johnston SRD, Hegg R, Im S-A, *et al.* Phase III, Randomized Study of Dual Human
51 1049 Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus
52 1050 Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal
53 1051 Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast. *J. Clin.*
54 1052 *Oncol.* , JCO.20.01894 (2020).
55
56
57
58
59
60

- 1
2
3 1053 92. Park JH, Kang MJ, Ahn JH, *et al.* Phase II trial of neoadjuvant letrozole and lapatinib in
4 1054 Asian postmenopausal women with estrogen receptor (ER) and human epidermal
5 1055 growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the
6 1056 TILs, ER expressional change after ne. *Cancer Chemother. Pharmacol.* 78(4), 685–695
7 1057 (2016).
8
9
10 1058 93. Rimawi M, Cecchini R, Rastogi P, *et al.* Abstract S3-06: A phase III trial evaluating pCR
11 1059 in patients with HR+, HER2-positive breast cancer treated with neoadjuvant
12 1060 docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen
13 1061 deprivation: NRG Oncology/NSABP B-52. In: *General Session Abstracts*, American
14 1062 Association for Cancer Research, S3-06-S3-06 (2017).
15
16
17 1063 94. Martin M, Holmes FA, Ejlertsen B, *et al.* Neratinib after trastuzumab-based adjuvant
18 1064 therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised,
19 1065 double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 18(12), 1688–1700
20 1066 (2017).
21
22 1067 95. Schwarz LJ, Croessmann SE, Avogadri-Connors F, Cutler RE, Lalani AS, Arteaga CL.
23 1068 Abstract 4818: Neratinib/fulvestrant but not fulvestrant alone maintain complete
24 1069 responses after treatment with trastuzumab/paclitaxel of mice bearing ER+/HER2+
25 1070 xenografts. *Cancer Res.* 77(13 Supplement), 4818 LP – 4818 (2017).
26
27
28 1071 96. Sudhan DR, Schwarz LJ, Guerrero-Zotano A, *et al.* Extended adjuvant therapy with
29 1072 neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete
30 1073 responses of ER β /HER2 β breast cancers: Implications to the EXTENET trial. *Clin.*
31 1074 *Cancer Res.* 25(2), 771–783 (2019).
32
33 1075 97. Chong QY, You ML, Pandey V, *et al.* Release of HER2 repression of trefoil factor 3
34 1076 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary
35 1077 carcinoma. *Oncotarget.* 8(43), 74188–74208 (2017).
36
37
38 1078 98. Turnbull AK, Webber V, McStay D, *et al.* Abstract P1-18-07: Can some ER+/HER2+
39 1079 patients be safely spared from treatment with chemotherapy plus herceptin? *Cancer*
40 1080 *Res.* 80(4 Supplement), P1-18-07 LP-P1-18-07 (2020).
41
42 1081 99. Kanaya N, Somlo G, Wu J, *et al.* Characterization of patient-derived tumor xenografts
43 1082 (PDXs) as models for estrogen receptor positive (ER+HER2– and ER+HER2+) breast
44 1083 cancers. *J. Steroid Biochem. Mol. Biol.* 170, 65–74 (2017).
45
46 1084 100. A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination
47 1085 With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor
48 1086 Positive, HER2+ Metastatic Breast Cancer - ClinicalTrials.gov.
49
50
51 1087 101. Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive
52 1088 Metastatic Breast Cancer - ClinicalTrials.gov.
53
54 1089 102. An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In
55 1090 Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive
56 1091 Breast Cancer - ClinicalTrials.gov.
57
58 1092 103. A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or
59 1093 Metastatic Breast Cancer - ClinicalTrials.gov.
60

- 1
2
3 1094 104. Study Evaluating Hemay022 in Combination With Exemestane In Subjects With ER
4 1095 Positive and HER2 Positive Advanced Breast Cancer - ClinicalTrials.gov.
5
6 1096 105. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat
7 1097 Metastatic Breast Cancer - ClinicalTrials.gov.
8
9 1098 106. Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor
10 1099 Receptor 2 Positive (HER2+) Metastatic Breast Cancer - ClinicalTrials.gov.
11
12 1100 107. To Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-
13 1101 positive Breast Cancer (TOUCH) - ClinicalTrials.gov.
14
15 1102 108. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant
16 1103 Chemotherapy in HER2-Positive Breast Cancer. *N. Engl. J. Med.* 353(16), 1659–1672
17 1104 (2005).
18
19 1105 109. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant
20 1106 chemotherapy in HER2-positive breast cancer: a randomised controlled trial. *Lancet.*
21 1107 369(9555), 29–36 (2007).
22
23 1108 110. Loi S, Dafni U, Karlis D, et al. Effects of Estrogen Receptor and Human Epidermal
24 1109 Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab A Secondary Analysis
25 1110 of the HERA Trial. *JAMA Oncol.* 2(8), 1040–1047 (2016).
26
27 1111 111. Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years' follow-up of trastuzumab
28 1112 after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of
29 1113 the HERceptin Adjuvant (HERA) trial. *Lancet.* 389(10075), 1195–1205 (2017).
30
31 1114 112. Johnston S, Pippin J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole
32 1115 and placebo as first-line therapy for postmenopausal hormone receptor - Positive
33 1116 metastatic breast cancer. *J. Clin. Oncol.* 27(33), 5538–5546 (2009).
34
35 1117 113. Sherrill B, Amonkar MM, Sherif B, Maltzman J, O'Rourke L, Johnston S. Quality of Life
36 1118 in Hormone Receptor-Positive HER-2 + Metastatic Breast Cancer Patients During
37 1119 Treatment with Letrozole Alone or in Combination with Lapatinib . *Oncologist.* 15(9),
38 1120 944–953 (2010).
39
40 1121 114. Chan A, Delalogue S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant
41 1122 therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre,
42 1123 randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 17(3),
43 1124 367–377 (2016).
44
45 1125 115. Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal
46 1126 Women With ER and Her2 Positive Breast Cancer - ClinicalTrials.gov.
47
48 1127 116. A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase
49 1128 Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2
50 1129 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer -
51 1130 ClinicalTrials.gov.
52
53 1131 117. Llombart-Cussac A, Cortés J, Paré L, et al. HER2-enriched subtype as a predictor of
54 1132 pathological complete response following trastuzumab and lapatinib without
55 1133 chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label,

- 1
2
3 1134 single-group, multicentre, phase 2 trial. *Lancet Oncol.* 18(4), 545–554 (2017).
4
5 1135 118. PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade
6 1136 in HER2-positive Early Breast Cancer - [ClinicalTrials.gov](https://clinicaltrials.gov).
7
8 1137 119. Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before,
9 1138 During and After Treatment - [ClinicalTrials.gov](https://clinicaltrials.gov).
10
11 1139
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Review Only

1 **Table 1 Current clinical trials treating HR+/HER2+ breast cancer. (Oestrogen receptor, ER; Hormone receptor, HR; Aromatase inhibitor, AI; Human**
 2 **epidermal growth factor receptor, HER; ado-trastuzumab emtansine, T-DM1; Epidermal growth factor receptor, EGFR).**

Trial	Phase	Recruitment	Cohort size	Menopausal status	Cancer stage	Breast cancer type	Treatment group (s)
AI in combination with lapatinib, trastuzumab or both (ALTERNATIVE) (Clinical Trial NCT01160211)	III	2011-2020	355	Post	Metastatic	HR+/HER2+ breast cancer	Lapatinib with trastuzumab and an AI v. trastuzumab and an AI v. lapatinib and an AI [100]. Recently published results show PFS benefit in the lapatinib with trastuzumab and an AI group compared to trastuzumab plus AI group [91].
Palbociclib and Trastuzumab With Endocrine Therapy in HER2+ Metastatic Breast Cancer (PATRICIA) (Clinical Trial NCT02448420)	II	2015-ongoing	232 (estimated enrolment)	Both	Locally Advanced or Metastatic	HR+/HER2+ breast cancer	Palbociclib, trastuzumab and endocrine therapy v. T-DM1 or chemotherapy in combination with trastuzumab (physician's choice) who previously received at least 1 anti-HER2 regimen [101].
Ribociclib (Lee011) In Combination With Trastuzumab Or T-DM1 (Clinical Trial NCT02657343)	1b/II	2016-ongoing	26	Both	Metastatic or advanced	HER2+ breast cancer, some of which are also ER+	Ribociclib and T-DM1 v. ribociclib and trastuzumab v. ribociclib, trastuzumab and fulvestrant [102].
Abemaciclib (LY2835219) in HR+/HER2+ Breast Cancer (monarchHER) (Clinical Trial NCT02675231)	II	2016-ongoing	237	Post	Locally Advanced or Metastatic	HR+/HER2+ breast cancer	Abemaciclib with trastuzumab with or without fulvestrant or chemotherapy [90]. Recently published results show abemaciclib, fulvestrant and trastuzumab combination treatment not only proved tolerable and safe but also improved PFS compared to standard-of-care trastuzumab plus chemotherapy [103].

Hemay022 in Combination with Exemestane (Clinical Trial NCT03308201)	I	2017-ongoing	48 (estimated enrolment)	Post	Metastatic or advanced	ER+/HER2+ breast cancer	EGFR inhibitor Hemay022 with exemestane [104].
Neratinib with Fulvestrant in HER2+/ER+ Metastatic Breast Cancer (Clinical Trial NCT03289039)	II	2017-ongoing	152 (estimated enrolment)	Both	Locally advanced Metastatic	ER+/HER2+ breast cancer	Neratinib with fulvestrant or neratinib alone [65].
Palbociclib to Treat Metastatic Breast Cancer (PATINA) (Clinical Trial NCT02947685)	III	2017-ongoing	496 (estimated enrolment)	Both	Metastatic	ER+/HER2+ breast cancer	Anti-HER2 therapy (trastuzumab/pertuzumab) with endocrine therapy (letrozole, anastrozole, exemestane or fulvestrant) with or without palbociclib [105].
Palbociclib in ER+/HER2+ metastatic breast cancer (Clinical Trial NCT03709082)	I/II	2018-ongoing	4 (estimated enrolment)	Post	Metastatic	ER+/HER2+ breast cancer	Palbociclib, letrozole and T-DM1 [106].
TOUCH (Clinical Trial NCT03644186)	II	2019-ongoing	144 (estimated enrolment)	Post	Early breast cancer	Elderly patients with HR+/HER2+ breast cancer	Neoadjuvant palbociclib with both hormonal therapy and anti-HER2 therapy v. treatment with paclitaxel and anti-HER2 therapy (standard of care) [107].

Table 2 Targeted treatments available, alone or in combination, for the treatment of HR+ and/or HER2+ breast cancer. (Oestrogen receptor, ER; Hormone receptor, HR; Aromatase inhibitor, AI; Selective oestrogen receptor downregulator/degrader, SERD; Human epidermal growth factor receptor, HER; Epidermal growth factor receptor, EGFR).

Drug	Commercial Brand Name(s)	Type of drug	Target	For which patients
Tamoxifen	Nolvadex, Tamosin, Emblon, Tamofen	ER modulator	ER	HR+ (premenopausal)
Letrozole	Femara	AI	Aromatase	HR+ (postmenopausal)
Anastrozole	Arimidex	AI	Aromatase	HR+ (postmenopausal)
Exemestane	Aromasin	AI	Aromatase	HR+ (postmenopausal)
Fulvestrant	Fasodex	SERD	ER	Metastatic ER+/HER2- (postmenopausal who have recurred on endocrine therapy)
Trastuzumab	Herceptin	Monoclonal antibody	Extracellular domain of HER2	HER2+
Pertuzumab	Perjeta	Monoclonal antibody	Extracellular domain of HER2 (different one than trastuzumab)	HER2+
Lapatinib	Tyverb, Tykerb	Tyrosine kinase inhibitor	HER1 (EGFR) & HER2	HER2+
Neratinib	Nerlynx	Tyrosine kinase inhibitor	HER1, HER2, and HER4	Extended adjuvant treatment following trastuzumab in HER2+ (including ER+/HER2+) patients
Trastuzumab emtansine (T-DM1)	Kadcyla	Antibody-drug conjugate	HER2	HER2+ breast cancer that has recurred
Trastuzumab deruxtecan	Enhertu	Antibody-drug conjugate	HER2	Metastatic HER2+ breast cancer patients who have received two or more prior anti-HER2 therapies in the metastatic setting
Palbociclib	Ibrance	CDK4/6 inhibitor	CDK4/6	HR+/HER2- breast cancer
Ribociclib	Kisqali	CDK4/6 inhibitor	CDK4/6	HR+/HER2- breast cancer
Abemaciclib	Verzenio, Verzenios	CDK4/6 inhibitor	CDK4/6	Locally advanced or metastatic HR+/HER2- breast cancer patients who previously received endocrine therapy

10

11 **Table 3 Previous clinical trials treating HR+/HER2+ breast cancer. (Oestrogen receptor, ER; Hormone receptor, HR; Progression-free survival, PFS; Human epidermal**
 12 **growth factor receptor, HER; Pathological complete response, pCR; Aromatase inhibitor, AI).**

Trial	Phase	Recruitment	Cohort size	Menopausal status	Cancer stage	Breast cancer type	Treatment groups	Results (HR+/HER2+ tumours)
Herceptin Adjuvant Trial (HERA)	III	2001-2005	5099	Post	Early-stage	HER2+ breast cancer	Trastuzumab or no trastuzumab for 1 or 2 years, following adjuvant chemotherapy	Patients with ER+/HER2+ breast cancers but with a low HER2 FISH ratio or higher <i>ESR1</i> levels receive less benefit from adjuvant trastuzumab after chemotherapy[108][109][110][111].
TAnDEM (Clinical Trial NCT00022672)	III	2001-2004	207	Post	Metastatic	HR+/HER2+ breast cancer previously treated with tamoxifen	Anastrozole alone or with trastuzumab but no chemotherapy	There was a significant improvement in PFS for the group that received anastrozole plus trastuzumab in combination [63].
EGF30008 (Clinical Trial NCT00073528)	III	2003-2006	219	Post	Metastatic	HR+ breast cancer	Lapatinib combined with letrozole or letrozole with placebo for first-line therapy	In HR+/HER2+ cancers, the combination of lapatinib and letrozole showed an increase in PFS compared to those who received letrozole with placebo [112][113].
Efficacy and Safety of Letrozole combined with Trastuzumab (eLEcTRA)	III	2003-2007	57	Post	Metastatic	HR+/HER2+ breast cancer	Trastuzumab with letrozole or letrozole alone as first-line treatment	Better outcomes, including time to progression and clinical benefit, were seen in those treated with the combined trastuzumab plus letrozole treatment [64].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

ExteNET (Clinical Trial NCT00878709)	III	2009-2011	2840	Post	Stage I-III	HER2+ breast cancer previously received neoadjuvant and adjuvant trastuzumab	Neratinib	12 months treatment with neratinib significantly improved 2-year invasive disease-free survival; the benefit from neratinib was greater in HR+ patients [93][114].
Neo-ALL-IN (Clinical Trial NCT01275859)	II	2010-2012	24	Post	Stage II-III	ER+/HER2+ breast cancer	Neoadjuvant letrozole and lapatinib for 18-21 weeks before surgery	Overall clinical response rates were 62.5% however no pCR was achieved [92][115].
PERTAIN (Clinical Trial NCT01491737)	II	2012-2014	258	Post	Metastatic or locally advanced	HR+/HER2+ breast cancer patients who had not received prior therapy, with the exception of endocrine	Trastuzumab and an AI or trastuzumab, an AI and pertuzumab. Some also received chemotherapy	Greater PFS in the pertuzumab+trastuzumab+AI group but also more serious adverse events in the pertuzumab+trastuzumab+AI group [83][116].
PAMELA (Clinical Trial NCT01973660)	II	2013-2015	151	Both	Stage I-III A	HER2+ breast cancer	Lapatinib combined with trastuzumab (and letrozole or tamoxifen if HR+)	41% of patients with the HER2-enriched subtype and 10% of patients with non-HER2 enriched subtypes achieved pCR at the time of surgery. Patients with the HER2-enriched subtype may benefit the most from dual HER2 blockade [117][118].

1 2 3 4 5 6 7 8 9 10 11 12	NSABP B-52 trial	III	2014-2016	315	Both	Locally advanced (but not metastasised)	HR+/HER2+ breast cancer	A luteinizing hormone-releasing hormone agent or AI with docetaxel, carboplatin, trastuzumab, and pertuzumab neoadjuvant therapy	Depriving oestrogen along with docetaxel, carboplatin, trastuzumab, and pertuzumab treatment in the neoadjuvant setting improved pCR however this was not statistically significant [93].
13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	NA-PHER2 trial (Clinical Trial NCT02530424)	II	2015-2016	102	Both	Early (> 1.5 cm) or locally advanced untreated breast cancer	ER+/HER2+ breast cancer	Neoadjuvant treatment with trastuzumab, pertuzumab, palbociclib and fulvestrant	A clinical objective response was achieved for 29/30 patients, as well as a decrease in proliferation (assessed through Ki67 expression) following two weeks of treatment and at the time of surgery [79][119].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

14

For Review Only



Figure 1. Molecular subtypes of breast cancer and key receptor/biomarker expression. Oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and proliferation marker Ki67 expression status in Perou's five molecular subtypes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41




Figure 2. Crosstalk between the oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) signalling. In the presence of oestrogen, ER, which resides in both the cytoplasm and nucleus of a breast epithelial cell, can activate HER dimers and their downstream pathways (MAPK and AKT). In addition to the effects of these pathways, this signalling can also lead to modulation of active nuclear ER, which interacts with other transcription factors (TFs) and co-activators (CoAct) to regulate the expression of genes regulating processes essential to cell survival and cancer progression.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Luminal A

ER+ and/or PR+, HER2-, low Ki67

Luminal B

ER+ and/or PR+

HER2+/any Ki67 or
HER2-/high Ki67

HER2-enriched

ER- and/or PR-, HER2+

Basal

ER- and/or PR-, HER2-

Normal-like

<https://mc04.manuscriptcentral.com/fm-fon>
ER- and/or PR-, HER2-, low Ki67

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43

